




Fall 12-19-2019

## Gingival MSCs Improve Bone Phenotype in Ovariectomy-Induced Osteoporosis via Programmed Cell Death Pathway

Sultan Alghaithi

University of Pennsylvania, [alsult@upenn.edu](mailto:alsult@upenn.edu)

Follow this and additional works at: [https://repository.upenn.edu/dental\\_theses](https://repository.upenn.edu/dental_theses)

 Part of the [Biological Phenomena](#), [Cell Phenomena](#), and [Immunity Commons](#), [Cell Biology Commons](#), [Medical Immunology Commons](#), and the [Periodontics and Periodontology Commons](#)

---

### Recommended Citation

Alghaithi, Sultan, "Gingival MSCs Improve Bone Phenotype in Ovariectomy-Induced Osteoporosis via Programmed Cell Death Pathway" (2019). *Dental Theses*. 49.  
[https://repository.upenn.edu/dental\\_theses/49](https://repository.upenn.edu/dental_theses/49)

This paper is posted at ScholarlyCommons. [https://repository.upenn.edu/dental\\_theses/49](https://repository.upenn.edu/dental_theses/49)  
For more information, please contact [repository@pobox.upenn.edu](mailto:repository@pobox.upenn.edu).

---

# Gingival MSCs Improve Bone Phenotype in Ovariectomy-Induced Osteoporosis via Programmed Cell Death Pathway

## Abstract

Estrogen deficiency-related osteoporosis is a skeletal system disorder that affects women after menopause taking a toll on financial and health institutions. Gingival Mesenchymal Stem cells (GMSCs) are a distinctive population of dental tissue-derived stem cells that possess uniquely high proliferation abilities and are capable of self-maintenance and multipotent differentiation. Their use has been investigated in different disease model applications, including cutaneous wound healing models, colitis, and allergy-related inflammatory disease models, but their effect on the bone phenotype of ovariectomy-induced osteoporosis hasn't been explored. In our study, we show that a single systemic infusion of GMSCs elevated the bone mass reduction caused by Ovariectomy (OVX)-induced osteoporosis in both the femurs and mandibles of OVX mice, they also successfully rescued the function of the defective endogenous population of Bone Marrow Mesenchymal Stem Cells (BMMSCs). We saw that the systemic infusion of GMSCs exerted an immunomodulatory effect on the host, leading to the elevation of T-regulatory lymphocytes (T-regs) and the downregulation of T helper type 1 lymphocytes (Th1) levels in recipient OVX mice. Mechanistically, PD-1/PD-L1 is a popular cellular death pathway being heavily investigated in multiple research fields, In our study, we found that GMSC expresses PD-L1 and that the improved bone phenotype resulting from the GMSC infusion was via the programmed cell death (PD-1/PD-L1) pathway triggering activated T-cell apoptosis in the OVX mice, eventually resulting in an improvement of the bone phenotype.

## Degree Type

Thesis

## Degree Name

DScD (Doctor of Science in Dentistry)

## Primary Advisor


Songtao Shi

## Keywords

GMSC, Mesenchymal Stem cells, Post-menopausal osteoporosis, Estrogen deficiency, Cell-therapy

## Subject Categories

Biological Phenomena, Cell Phenomena, and Immunity | Cell Biology | Medical Immunology | Periodontics and Periodontology



**University of Pennsylvania  
School of Dental Medicine**

**Gingival MSCs Improve Bone Phenotype in Ovariectomy-  
Induced Osteoporosis via Programmed Cell Death Pathway**

**Sultan Alghaithi, BDS**

**A THESIS**

Submitted to the Faculty of Penn Dental Medicine in Partial Fulfillment of the  
Requirements for the Degree of Doctor of Science in Dentistry

**2019**

---

**Thesis Supervisor: Prof. Songtao Shi DDS, MS, PhD**

Former Chair and Professor

Department of Anatomy and Cell Biology

Adjunct Professor

Department of Oral and Maxillofacial Surgery / Pharmacology

## **Thesis Committee Members**

---

**Prof. Anh Le DDS, PhD**

**COMMITTEE CHAIRPERSON**

Chair and Norman Vine Endowed Professor of Oral Rehabilitation,  
Department of Oral & Maxillofacial Surgery

---

**Prof. Joseph Fiorellini DMD, DMSc**

Program Director,  
Department of Periodontics

---

**Prof. Sumin Lee DDS, MSD, DScD**

Assistant Professor  
Department of Endodontics



# Acknowledgments

First, I would like to express my utmost gratitude to my mentor and teacher Professor Shi. The support and expertise provided to me were essential and valuable in my journey, and he always made me eager to persevere even more and to never stop exploring. I am glad I had the honor and great opportunity to work with you.

Next, I would like to thank my committee members Dr. Anh Le, Dr. Joseph Fiorellini, and Dr. Sumin Lee. Each and every one of them I am forever in debt to as I genuinely appreciate them always making it possible to meet as well as taking the time from their busy schedules and continuously guide through their valuable input. I learned a lot from them, and their roles throughout the years were essential and greatly appreciated.

I would also like to thank the DScD program director Dr. Dana Graves, and the vice-chair of the department of basic & translational science at Penn Dental Medicine Dr. Kelly Jordan-Sciutto for giving me the opportunity back in 2014 to be a part of this great institute for my DScD studies. I also thank all Professor Shi's lab members for their help and for being a supportive family for the past five years and whom their friendships will definitely extend beyond my program.

Lastly, I am grateful for my wife's support, our beautiful newborn daughter Layan, my parents for everything they did as they brought me up, and my siblings for their continuous care, encouragement, and cheerleading. This would not have been possible without all of them.

# Abstract

Menopause, an event that occurs in all women's life cycle, attributes physiologically to a decreased ovarian function, and an associated decline in the female reproductive hormones. Manifestations include hot flashes, sleep disturbances, anxiety, depression, and other changes. A common disease affecting post-menopausal women is osteoporosis or "estrogen-deficiency related osteoporosis." Osteoporosis is a skeletal system disorder where bone mineral density progressively decreases, which in turn increases the risk of fragility related fractures. The underlying mechanism behind the estrogen-related osteoporosis, in general, is through estrogen being a key regulator of bone remodeling and regulating cytokines. When that balance is disrupted due to the lack of estrogen in menopause, an intensified bone resorption rate takes place without the adequate formation of new bone, correlated with the inflammatory nature of the post-menopausal osteoporosis disorder. Multiple treatment modalities are utilized for the treatment and management of osteoporosis, but there are drawbacks that confound their use. Among several efforts and reports on alternative methods and approaches for better treatment options in osteoporosis and bone diseases, cellular therapy, a promising method which was profoundly investigated, has evolved noticeably in recent years as a powerful investigation tool in the field of bone biology, and related bone disorders.

Mesenchymal Stem Cells (MSCs) are adult stem cells that act as a viable source of cell for cell replacement to treat bone disease due to their inherent properties of self-renewal and plasticity. Another benefit they have is their potent immunomodulatory ability to induce immunological tolerance in the recipient host, which makes them a desired tool for investigations in developing new treatment modalities for immune-related diseases. Dental tissue-derived stem cells are stem cells harvested from the oral cavity, with several promising ongoing investigated applications including bio-root engineering, regeneration of periodontal defects, pulpal tissue engineering, and calvarial defects regeneration and they show promising outcomes. In this thesis project, we investigate the application and properties of Gingival Mesenchymal Stem Cells (GMSCs). These cells are adult, tissue-specific stem cells with several reported clinical applications in multiple murine disease models, including wound healing models, colitis models, and allergy-related inflammatory disease models, and the results were promising. The availability of GMSCs is also considerably high, and there is reduced morbidity associated with their harvesting procedures in comparison to other types of stem

cells. GMSCs possess immunomodulatory properties and can modulate the microenvironment of the recipient host and are capable of multipotent differentiation into multiple cell types. These benefits of GMSCs prompted us to further want to explore their therapeutic effect in a chronic inflammatory disease model, the estrogen deficiency-induced osteoporosis model.

In this dissertation, we investigated the application of GMSCs as a novel cellular therapeutic approach in an attempt to ameliorate the bone phenotype of estrogen deficiency-induced osteoporosis in the OVX mouse model. Our findings demonstrate that the single transplantation of GMSCs was able to markedly improve the bone phenotype, as seen in both the femurs and mandibles of OVX mice. In addition to that, our investigations also showed that the GMSCs transplantation was able to rescue the osteogenic functions of the endogenous population of Bone Marrow Mesenchymal Stem Cells (BMMSCs) in the recipient ovariectomized mice. Furthermore, to explore the mechanisms underlying the improved bone phenotype and inflammatory state associated with the estrogen-induced osteoporosis model, we examined possible pathways that may be involved. We showed that GMSCs exerted an immunoregulatory effect on the recipient host via the PD-L1/PD-1 pathway. Using the siRNA approach to knockdown PD-L1 in GMSCs (siPdl1 GMSCs) or an anti-PDL1 drug (Atezolizumab) treatment, we showed a diminished effect of the GMSCs infusion on the OVX bone phenotype, suggesting the role of PD-L1 as an immune checkpoint in the GMSCs-mediated effect in the ovariectomized mouse model. Furthermore, at the cellular level, GMSCs-treated mice showed a decreased expression of Th1, Th17, and an increase in the expression of T-reg as compared to OVX mice. On the other hand, siPdl1 GMSCs-treated mice displayed similar expression of Th1, T-reg, and a decreased expression of Th17 as compared to OVX mice.

In conclusion, cell-based therapy using GMSCs can improve the osteoporotic bone phenotype, as well as rescue the function of the endogenous populations of BMMSCs in the estrogen deficiency OVX mouse model of osteoporosis, and the PD-L1/PD-1 pathway plays a role in the GMSCs mediated effects seen in the OVX mice.

# Table of Contents

<b>Acknowledgments.....</b>	<b>iii</b>
<b>Abstract.....</b>	<b>iv</b>
<b>Table of contents.....</b>	<b>vi</b>
<b>List of abbreviations.....</b>	<b>vii</b>
<b>List of illustrations.....</b>	<b>xi</b>
<b>Introduction.....</b>	<b>1</b>
Osteoporosis.....	1
Menopause and postmenopausal osteoporosis.....	3
Current treatment modalities.....	4
Cell therapy and stem cells.....	6
Dental-tissues derived stem cells.....	8
Gingival mesenchymal stem cells.....	11
Hypothesis.....	12
<b>Specific aims.....</b>	<b>14</b>
<b>Materials and methods.....</b>	<b>15</b>
Animals and induction of estrogen-deficiency related osteoporosis .....	15
Isolation and preparation of mouse GMSCs.....	17
Computed Microtomography and analysis of datasets.....	19
Histological and histomorphometry analysis.....	19
In-vivo Oil Red O staining / fatty marrow Analysis.....	21
Enzyme Linked Immunosorbent Assay (ELISA).....	21
Isolation and culture of mouse BMMSCs.....	22
Transplantation of BMMSCs into immunocompromised mice.....	22
Proliferation capacity analysis / BrdU labeling assay.....	23
In-vitro osteogenic differentiation capacity analysis.....	23
In-vitro adipogenic differentiation capacity analysis.....	24
Western immunoblotting.....	24
Flow cytometry .....	25
Immunofluorescent microscopy.....	26
siRNA transfection.....	27
T-cell apoptosis assay.....	27
Statistics.....	28
<b>Results.....</b>	<b>29</b>
<b>Disucssion.....</b>	<b>79</b>
<b>Conclusions .....</b>	<b>92</b>
<b>References.....</b>	<b>93</b>

# List of Abbreviations

- MSCs: Mesenchymal stem cells
- BMMSCs: Bone marrow mesenchymal stem cells
- GMSCs: Gingival mesenchymal stem cells
- DPSCs: Dental pulp stem cells
- SHED: Stem cells from human exfoliated deciduous teeth
- PDLSc: Periodontal ligament stem cells
- DFPCs: Dental follicle precursor cells
- SCAP: Stem cells from apical papilla
- OVX: Ovariectomized mice model
- BRONJ: Bisphosphonate related osteonecrosis of the jaw
- DDS: Dextran sulfate sodium
- TNF-A: tumor necrosis factor alpha
- IL-6: Interleukin 6
- IL-1: Interleukin 1

- IFN- $\gamma$ : Interferon gamma
- M-CSF: Macrophage colony-stimulating factor
- GM-CSF: Granulocyte-macrophage colony-stimulating factor
- RANKL: Receptor activator of nuclear factor kappa-B ligand
- TGF-B: Transforming growth factor Beta
- NIH: National institute of health
- BMD: Bone mineral density
- DXA: Dual-energy x-ray absorptiometry
- WHO: World health organization
- SERMs: Selective estrogen receptor modulators
- PTH: Parathyroid hormone
- ASGCT: American society of gene & cell therapy
- CDs: Cluster differentiation molecules
- OCT-4: Octamer-4
- SSEA-4: Stage-specific embryonic antigen 4
- PBS: Phosphate buffered saline

- μCT: X-ray microtomography
- TRAP: Tartrate-resistant acid phosphatase
- H&E: Hematoxylin and eosin
- EDTA: Ethylenediaminetetraacetic acid
- ELISA: Enzyme-linked Immunosorbent assay
- PFA: Paraformaldehyde
- BV/TV: Bone volume density
- Conn.D: Connectivity density
- SMI: Structure model index
- BRDU: Bromodeoxyuridine
- TNF-R: Tumor necrosis factor receptor
- DISC: Death inducing signaling complex
- WT: Wild type
- IBD: Irritable bowel disease
- SLE: Systemic lupus erythematosus
- DSS: Dextran sulfate sodium

- SS: Systemic sclerosis
- GVHD: Graft versus host disease
- CFU-F: Colony forming units – fibroblast
- LPL: Lipoprotein lipase
- PPAR- $\gamma$ : Peroxisome proliferator-activated receptor gamma
- RUNX2: Runt-related transcription factor 2
- ALP: Alkaline phosphatase
- WT: Wild type
- PBS: phosphorus buffered saline
- BRONJ: Bisphosphonate related osteonecrosis of the jaw
- MAR: Mineral apposition rate
- FDA: Food and drug administration



# List of Illustrations

<b>Figure 1.</b> Risk factors for osteoporosis.....	2
<b>Figure 2.</b> Different potential cell lineages of MSCs.....	8
<b>Figure 3.</b> Study groups.....	15
<b>Figure 4.</b> Experimental timeline.....	16
<b>Figure 5.</b> GMSC's expression of common MSC markers.....	18
<b>Figure 6.</b> Computed microtomography analysis of femurs.....	30
<b>Figure 7.</b> Histological analysis of femurs.....	34
<b>Figure 8.</b> TRAP <sup>+</sup> cells analysis of femurs.....	36
<b>Figure 9.</b> Oil-Red-O staining/in-vivo analysis of fatty marrow.....	38
<b>Figure 10.</b> Dynamic bone histomorphometry.....	39
<b>Figure 11.</b> Computed microtomography analysis of mandibles.....	40
<b>Figure 12.</b> Histological analysis of mandibles.....	42
<b>Figure 13.</b> Blood serum markers analysis.....	43
<b>Figure 14.</b> Colony forming units-fibroblast assay.....	47
<b>Figure 15.</b> BRDU cell proliferation analysis.....	48
<b>Figure 16.</b> Osteogenic differentiation assay.....	49
<b>Figure 17.</b> Expression levels of osteogenic proteins.....	50
<b>Figure 18.</b> Adipogenic differentiation capacity assay.....	51
<b>Figure 19.</b> Expression levels of adipogenic proteins.....	52
<b>Figure 20.</b> In-vivo bone formation capacity assay.....	53
<b>Figure 21.</b> FAS/FASL pathway testing group assignment.....	55

<b>Figure 22.</b> Computed microtomography analysis of Fas <sup>-/-</sup> , FasL <sup>-/-</sup> GMSCs treatment.....	56
<b>Figure 23.</b> Histological analysis of femurs.....	58
<b>Figure 24.</b> TRAP <sup>+</sup> cell analysis of femurs.....	60
<b>Figure 25.</b> Proposed mechanism involving GMSCs suppression of T-Cells.....	62
<b>Figure 26.</b> Study groups of PD-1/PD-L1 pathway mechanistic investigation.....	62
<b>Figure 27.</b> Expression levels of PD-L1 protein.....	63
<b>Figure 28.</b> Immunohistochemistry analysis of PD-L1/MSc marker expression levels.....	64
<b>Figure 29.</b> Computed microtomography analysis of siPd1 GMSCs treatment.....	65
<b>Figure 30.</b> Histological analysis of femurs.....	67
<b>Figure 31.</b> TRAP <sup>+</sup> cells analysis of femurs.....	68
<b>Figure 32.</b> Oil-Red-O staining/in-vivo analysis of fatty marrow.....	70
<b>Figure 33.</b> Study groups of PD-L1 drug therapy investigation.....	72
<b>Figure 34.</b> Experimental timeline of treatment.....	72
<b>Figure 35.</b> Femur Micro-CT images and analysis of Atezolizumab and placebo groups.....	73
<b>Figure 36.</b> Flow cytometry analysis of Th-1, Th-17 and T-reg levels.....	74
<b>Figure 37.</b> T-cell apoptosis assay.....	77

# Introduction

## Osteoporosis:

The national institute of health (NIH) describes osteoporosis as a skeletal system disorder occurring due to the reduction of bone density, which in turn leads to an increased risk of bone fractures (1). The disease resembles a growing worldwide concern, and it is estimated that today, over 200 million people worldwide are diagnosed with the disease (2). From a physiological point of view, the disease of osteoporosis occurs when there is an imbalance between bone formation and bone resorption rates, this could happen by either a decrease in the bone formation rates or an increase in bone resorption rates. The disease is also a chronic and silent disease in nature, up until it reaches the point of clinical detection or manifestation or until an incident of bone fracture occurs (3).

The diagnosis of the disease is a process that mainly involves an overall assessment of the subject's bone mineral density value (BMD), which is measured by different available diagnostic means, such as the dual-energy x-ray absorptiometry (DXA) scan. Then if the value obtained is equal to or more than 2.5 standard deviations less than the reference young adult mean value, they would be diagnosed with osteoporosis (4). Several risk factors for fractures are also taken into consideration when diagnosing patients, these multiple known risk factors for osteoporosis have been long investigated as well as reported in the literature over the years. Some of these factors leading to low bone mineral density and

osteoporosis are age, sex, race, estrogen levels, previous fragility-related fractures, and others (Fig.1). These investigations and researches aim to progressively better understand the relation of these risk factors to osteoporosis and fractures because of the considerable magnitude of the disease and impact of disability on societies as well as the significant toll of the increased financial weight for the costs associated with the treatment of osteoporosis-related fractures (5-9).

<b>General</b> <ul style="list-style-type: none"> <li>• Age: women 65 and older, men older than 70</li> <li>• Caucasian or Asian ethnicity</li> <li>• Family history of osteoporosis</li> <li>• Has experienced a low-impact fracture</li> <li>• Maternal or parental hip fracture</li> <li>• Postmenopausal status</li> </ul>		<b>Medications (Long-Term Therapy)</b> <ul style="list-style-type: none"> <li>• Aluminum (in antacids)</li> <li>• Anticonvulsant therapy (phenobarbital, phenytoin)</li> <li>• Aromatase inhibitor for breast cancer</li> <li>• GnRH analog for prostate cancer</li> <li>• Immunosuppressant agents</li> <li>• Long-term corticosteroid use (5 mg prednisone per day for three months or longer)</li> <li>• Long-term heparin use</li> <li>• Parenteral progesterone</li> <li>• Proton pump inhibitors</li> <li>• Supraphysiologic doses of thyroxine</li> <li>• Tamoxifen (premenopausal women)</li> <li>• Total parenteral nutrition</li> </ul>
<b>Lifestyle</b> <ul style="list-style-type: none"> <li>• Cannot rise from a chair for extended time</li> <li>• Cigarette smoking (active or passive)</li> <li>• High alcohol intake (three or more drinks per day)</li> <li>• Sedentary lifestyle; low physical activity</li> </ul>		
<b>Nutrition</b> <ul style="list-style-type: none"> <li>• High caffeine consumption</li> <li>• Low calcium intake</li> <li>• Vitamin D deficiency</li> <li>• Thin: weight less than 127 lbs; BMI lower than 19</li> </ul>		
<b>Medical Conditions</b>		
<b>Cancer-related</b> <ul style="list-style-type: none"> <li>• Leukemia or lymphoma</li> <li>• Multiple myeloma</li> <li>• Solid organ or allogeneic stem cell transplantation</li> </ul>	<ul style="list-style-type: none"> <li>• Dialysis</li> <li>• Eating disorder (e.g., anorexia, bulimia)</li> <li>• Gastric bypass</li> <li>• Gastrointestinal surgery</li> <li>• Gaucher disease</li> <li>• Hemochromatosis</li> <li>• Hemophilia</li> <li>• HIV</li> <li>• Hyperparathyroidism</li> <li>• Hyperthyroidism</li> <li>• Hypogonadism</li> <li>• Hypophosphatasia</li> <li>• Idiopathic scoliosis</li> </ul>	<ul style="list-style-type: none"> <li>• Inflammatory bowel disease</li> <li>• Insulin-dependent diabetes</li> <li>• Malabsorption syndrome, including gastrectomy or bariatric surgery</li> <li>• Mastocytosis</li> <li>• Multiple sclerosis</li> <li>• Pernicious anemia</li> <li>• Rheumatoid arthritis</li> <li>• Severe liver disease</li> <li>• Spinal cord transection</li> <li>• Thalassemia</li> <li>• Weight loss</li> </ul>
<b>General</b> <ul style="list-style-type: none"> <li>• Amyloidosis</li> <li>• Ankylosing spondylitis</li> <li>• Celiac disease</li> <li>• Cerebral vascular accident</li> <li>• Chronic obstructive pulmonary disease</li> <li>• Congenital porphyria</li> <li>• Cushing syndrome</li> </ul>		

BMI—body mass index; GnRH—gonadotropin-releasing hormone

**Figure 1. Risk factors for osteoporosis.** Risk factors for osteoporosis and low bone mineral density. (Figure adapted from Wickham 2011(9))

### **Menopause and postmenopausal osteoporosis:**

Menopause is a risk factor for developing osteoporosis. The world health organization (WHO) defines menopause as "the permanent cessation of menstruation resulting from the loss of ovarian follicular activity." Moreover, it is estimated that in the united states, the yearly number of women reaching menopause is around 1.5 million, while menopause occurs in every woman's life cycle, it is marked beginning with the first missed period of 12 consecutive months of menstrual cycle termination. The average age for which menopause occurs is around 50 years, and it is characterized by multisymptomatic changes, mainly vasomotor symptoms such as hot flashes, night sweats, and flushes. It is also accompanied by a decrease in ovarian hormones, mainly Estrogen, this decline reaches its maximum level of decrease 3 to 4 years from the last occurring menstrual cycle (10-12). The effects of this decrease also involve the skeletal system and are linked to osteoporosis in post-menopausal women leading to a disruption of the existing balance between bone formation and bone resorption rates. Furthermore, even though the mechanism behind it is yet to be fully understood, the effect of Estrogen on the bone is known to be primarily by its modulation capabilities of cytokine production and blocking osteoclastogenesis, as well as indirectly increasing the absorption of calcium from the intestines, and decreasing the renal output of calcium (13,14).

In addition to the effect of Estrogen on the decrease in bone resorption rates, it is further known to promote osteoclast apoptosis directly by the increase in TGF- $\beta$  production (15). In menopause, when the levels of estrogen decrease,

an increase in some pro-inflammatory cytokines has been described, which in turn, increases osteoclast formation and inhibits their apoptosis; it also influences other cytokines affecting osteoclast differentiation such as IL-6, Macrophage Colony-Stimulating Factor (M-CSF), and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (16,17). In addition to the effect on cytokines, the immune system's T-lymphocytes are recognized too as key players in modulating the adverse effects on the bone from Estrogen deficiency and the noted increase in the inflammatory cytokines by the production of IFN- $\gamma$ , and TNF- $\alpha$  which in turn intensifies the effect of M-CSF and RANKL induced osteoclastogenesis (18,19). Overall, estrogen has an anti-inflammatory effect and it has been shown that OVX mice exhibit an increase in inflammation and a shortened life span. (20)

### **Current treatment modalities:**

Multiple approaches to the intervention of osteoporosis have been reported in the literature. Those interventions could be classified as either pharmacological or non-pharmacological based interventions. Non-pharmacological interventions incorporate dietary and lifestyle recommendations that include calcium or vitamin D intake and exercise routines (1). On the other hand, pharmacologic based interventions like antiresorptive agents include the widely-used bisphosphonates class of medications, a class of drugs that reduces bone resorption by increasing the apoptosis of osteoclasts (21). Some of the different bisphosphonates class drugs used for the treatment of osteoporosis are alendronate (22), Risedronate (23), and Ibandronate (24). These drugs have been evaluated for their use in post-

menopausal osteoporosis and reported to be efficient. However, although their efficiency in treatment, their use has been connected to complications such as osteonecrosis of the jaw and atypical femur fractures (25,26). Another class of antiresorptive agents that have been used in osteoporosis treatment includes Estrogens and selective estrogen receptor modulators (SERMs) (27,28). In addition to the reported drawbacks that are linked to bisphosphonates, with hormonal replacement therapy, there have been reports of their association with breast cancer and some cardiovascular events (29,30).

Moreover, an additional pharmacological class of drugs available are the anabolic agents, these act on the enhancement of bone formation rates rather than decreasing the bone resorption rates, an excellent example for anabolic agents is the parathyroid hormone (PTH). It is a well-known potent inducer of bone matrix synthesis, and it increases osteoblast activation while decreasing their apoptosis (31). Its use has been investigated in the treatment of osteoporosis, and its use in both the animal and human models and the animal model shows improvement in the bone mass and strength, those in human trials involving both genders show a pronounced increase in the spinal bone mineral density in contrast to those reported with antiresorptive agents (32). However, a reported setback of PTH includes the fact that an incidence of osteosarcoma was reported when studied in animals for two years period of use in a different variety of doses of PTH. Thus, recommendations have been made against its use for prolonged periods of time (33). Considering these setbacks that might be a limitation to the utilization of these medications, there is a constant need for the development of novel treatment


approaches as further viable options in the management and treatment of osteoporosis. Moreover, with the available current day advancements revolving around cell therapy applications in the field of research and bone diseases, a cell therapy-based approach without adverse effects or detrimental drawbacks would be a promising alternative method to be utilized as a novel treatment in the management and alleviation of osteoporosis and potentially other chronic illnesses.

### **Cell therapy and stem cells:**

The term cell therapy is prescribed by the American Society of Gene & Cell Therapy (ASGCT) as "the administration of live whole cells or maturation of a specific cell population in a patient for the treatment of a disease" (34). Their application is continuously investigated in disease applications and stem cells are believed to be a valuable source in cell therapy of bone diseases due to their ability to directly replace damaged tissues as well as their influence on cellular mechanisms of recovery (35). Mesenchymal stem cells (MSCs) were first reported around the 1960s by A.J. Friedenstein; it was when the observation he made was that bone marrow cells contain a population of cells that were capable of self-maintenance and to differentiate into multiple mesenchymal cell lineages (36). In addition to self-maintenance, these stem cells are cells that are available after birth; they are multipotent, and capable of giving rise to various cell types, including those of mesodermal (i.e., bone or cartilage cells), endodermal (i.e., muscle cells), and ectodermal (i.e., epithelial cells) lineages (Fig.2) (37,38). Cluster



Differentiation molecules (CD) are amongst the methods used in the process of identifying stem cells. Some of the markers that are commonly used to identify MSCs include, CD105, CD73, CD44, CD90, CD71, CD271, and the STRO-1 antibody also recognizes them (38). As for their sources, MSCs have been isolated and mainly named after their origin, they have been harvested from multiple parts in the body, primarily from bone marrow and it is the most common source of MSCs, other sources are the adipose tissues, placenta, umbilical cord, Wharton's jelly, and dental tissues (39). Both MSCs isolated from bone marrow and dental-tissues fit the criteria set by the international society for cellular therapy to define multipotent mesenchymal stem cells (40). Those isolated from bone marrow are reported to be able of giving rise to different cell types such as osteocytes, chondrocytes, adipocytes, hepatocytes, neuronal cells, cardiomyocytes, and pancreatic cells. Additionally, those derived from dental-tissues are reported to have the capacity to differentiate into osteocytes, chondrocytes, adipocytes, pancreatic cells, melanocytes, and neuronal cells (39,41). These multipotential differentiation characteristics made stem cells an attractive treatment option for investigations in disease research fields. The National Institute of Health (NIH) currently reports on [clinicaltrials.gov](http://clinicaltrials.gov) over a thousand clinical trials in different investigation phases ranging from phase I to phase IV investigating and related to MSC cell therapy. Trials reported include researches in the fields of bone defects in different regions, cutaneous wounds, urinary system cartilaginous defects, cardiovascular disorders, autoimmune diseases, liver diseases, and many other chronic illnesses (42).



**Figure 2. Different potential cell lineages of MSCs.** Potential for differentiation of BMMSCs to give rise to different cell types. (Diagram adapted from Uccelli 2008 (38))

### **Dental tissue derived stem cells:**

In addition to the previously mentioned different sources for isolation of stem cells, it is reported in the literature that stem cells derived from the oral cavity include several types of cells including Dental Pulp Stem Cells (DPSCs) (43), Stem Cells from Human Exfoliated Deciduous Teeth (SHED) (44), Periodontal Ligament

Stem Cells (PDLSCs) (45), Stem Cells from Apical Papilla (SCAP) (46), Dental Follicle Precursor Cells (DFPCs) (47), Gingival Mesenchymal Stem Cells (GMSCs) (48), and a more recently reported type that was discovered in 2013 by Marrelli et al and is considered an additional source of stem cells which is human periapical cysts and it was named Human Periapical Cyst-Mesenchymal Stem Cells (hPCy-MSCs) (49).

These dental tissues derived stem cells can give rise to lineages like those of BMMSCs, and they are shown to be neural crest-derived in origin, their application has been investigated in both oral and non-oral applications. Some of their oral applications investigated include bio-root engineering, regeneration of periodontal defects, pulp tissue engineering, and regeneration (41). They have also been evaluated in non-oral cell therapy applications. Some of these regenerative investigations include using scaffolds seeded with DPSCs to accelerate defect healing and bone regeneration in calvaria of rats. (50), DPSCs were also reported to differentiate into corneal epithelial progenitors when seeded in contact lenses and delivered to human corneas indicating their potential application in eye diseases (51).

Moreover, SHED's application was investigated in Systemic Lupus Erythematosus (SLE) mouse model and showed a successful reversal of the disorders associated with the disease as well as elevating the levels of T-regulatory cells (52). SHED's application was also investigated in multiple disease models, including Parkinson's rat models, Liver disease mice models, as well as

Diabetes mellitus mice models, and researchers report promising outcomes (53-55).

In the field of bone disease research, amongst the multiple animal models available for the investigation of osteoporosis, a popular well-established model is the ovariectomy model (OVX). It is known to be a reliable model for research. The ovaries are surgically removed, which induces estrogen deficiency, and the animal loses 50% of their cancellous bone because of the procedure resembling an osteoporotic phenotype, one other model available is the glucocorticoid treated model where the animal is treated with glucocorticoids for seven days to induce bone loss. Investigators have widely utilized These types of small animals in the research of bone diseases (56). Up to date, the use of stem cells has been investigated for osteoporosis treatment from multiple sources, such as umbilical cord blood-derived stem cells, bone marrow mesenchymal stem cells, and adipose tissues derived stem cells (57). Several investigations utilized the use of BMMSC in the treatment of osteoporosis by using the OVX animal model as well. Hsiao et al. reported the use of systemic injection of labeled mice bone marrow MSCs and that they have been shown to home the bone marrow of the host two months post-injection and improve the bone density and volume in the OVX mouse model (58). Liu et al. also reported the use of human BMMSCs in the OVX mouse model and showed that single transplantation of stem cells successfully prevented the early phases of bone loss as well as significantly downregulated the levels of Th1, T17 and upregulated T-reg cells (59). These results verify the familiar role of BMMSCS in immunomodulation and their ability to suppress the proliferation of T-cells (60).

In addition to that, the ability of BMMSCs to inhibit proinflammatory cytokines such as TNF- $\alpha$  and IFN- $\gamma$  and increase the expression of anti-inflammatory cytokines such as IL-10 has also been reported (61). These characteristics of BMMSCs capability of improving the osteoporotic bone phenotype of OVX animals made them an attractive tool for further investigation and development in cell therapy. However, although BMMSCs are the most commonly researched source of stem cells, the morbidity associated with their collection is high, and the accessibility to them and their harvesting procedure is of a complex nature, as well as the number of cells able to be collected from the tissues is considered low (62). These reasons, amongst others, led investigators to explore further and research for alternative sources to use in cell therapy disease research.

### **Gingival mesenchymal stem cells:**

On the other hand, Gingival Mesenchymal Stem Cells (GMSCs) are also dental tissues derived stem cells isolated from the gingiva, and they have been characterized by self-renewal properties, multipotent differentiation abilities, and immunomodulatory effects and their availability is of abundance as they are easily obtained from donor gingival tissue (48,63,64). Their application has been investigated in different experimental disease models. Some of their uses include their application in the experimental colitis model, as reported by Zhang et al. In an induced dextran sulfate sodium (DSS) model of colitis representing an inflammatory bowel disease (IBD). A single infusion of GMSCs ameliorated the disease, lowered the rate of T-helper lymphocytes recruitment, increased the

levels of T-regulatory lymphocytes. Additionally, in chemotherapy-induced oral mucositis model, alleviation of the disease was evident by the reversal of body weight loss and the restoration of the broken down epithelial lining (65). In another disease model, a wound healing model that utilizes excisional cutaneous wounds was studied, accelerated wound closure was achieved, also a reduction in the local inflammatory cells and pro-inflammatory cytokines (64). GMSCs were also reported to successfully regenerate bony defects in the Mandible and Calvaria of rats by their direct participation in bone formation, and the recruitment of bone progenitor cells (66). The hallmark of stem cells from gingiva in different disease models is that those Gingival Stem Cells achieved promising outcomes mainly through the ability to decrease the levels of pro-inflammatory cytokines, and T-helper lymphocytes as well as the increase of T-regulatory lymphocytes (48,64). And, even though their use has been evaluated in the utilization of the mentioned above disease models, the therapeutic effect of their use as a potential approach for the amelioration and improvement of bony effects of osteoporosis has not been assessed in the Ovariectomy model.

In this dissertation, we hypothesized that the systemic infusion of GMSCs would improve the osteoporotic bone phenotype of the estrogen deficiency related inflammatory mouse model, rescue the overall functions of the endogenous populations of BMMSCs of the study animals, and that the GMSCs transplantation would exert an immunoregulatory effect on T-cells and would induce immunological tolerance leading to the improvement of the bone phenotype, we also hypothesized the involvement of a cell death pathway as mechanism of action

behind the GMSCs-mediated influence on T-cells. To test our hypotheses and explore and understand the effects of the GMSCs treatment on the osteoporotic mouse model, we proposed three specific aims as elaborated next.

# Specific Aims

**1- Specific Aim #1:** To investigate whether stem cell-based therapy using a single systemic transplantation of GMSC can improve the bone phenotype in the estrogen deficiency, ovariectomy (OVX)-induced osteoporosis mouse model.

**2- Specific Aim #2:** To explore the therapeutic effects of GMSCs in the OVX mouse model and to test the ability of GMSCs to rescue the biological functions of the defective endogenous BMMSC populations in the osteoporotic OVX mice.


**3- Specific Aim #3:** To delineate the mechanisms underlying the rescue of bone phenotype in osteoporotic OVX mice, specifically the immunomodulatory effect of GMSCs.



# Materials and Methods


## **Animals and the induction of estrogen-deficiency related osteoporosis:**

The Ovariectomized mouse model is a well-established model for bone disease research representing estrogen deficiency-related osteoporosis as a result of the loss of ovaries. Bone disease research utilizes C3H/HeJ mice due to their increase trabeculation in the bone. All animal experiments described in this dissertation were performed under institutionally approved protocols for the use of animal research under protocol #805478 approved by the University of Pennsylvania Institutional Animal Care and Use Committee (ICAU). In order to explore the effect of GMSCs on the bone phenotype of ovariectomized mice, 8-week-old female C3H/HeJ mice were purchased from Jackson Labs (Bar Harbor, ME, USA). Mice were then divided into three age-matched groups as illustrated in (Fig.3)



**Figure 3. Study groups.** Illustration of study groups assignment.

First group was the negative control group where the mice were not subjected to any surgical procedure nor treatment serving as a negative control. The second group was the OVX group, this group of mice received surgical ovariectomy procedure of both ovaries but did not receive any cellular infusion serving as the positive control group. The third group was the GMSC- treatment group, these mice received surgical ovariectomy of both ovaries then a single infusion of GMSCs as outlined in the following experimental timeline described in (Fig 4). The GMSC-treated mice group was systemically infused with  $2 \times 10^5$  mouse GMSCs.



**Figure. 4 Experimental Timeline.** Ovariectomy procedure done at 9 weeks to designated groups, GMSCs were injected into designated group intravenously via the tail vein.

The ovariectomy procedure was performed on C3H/HeJ mice using an electrocautery machine for maximum hemostasis achievement. A Two-weeks period was allowed for the OVX phenotype to be properly established; all mice were sacrificed at 4 weeks post-injection for subsequent examination. The sample size of the animals used in the experiments were at least an  $n = 5$  in each group.


Additional *Prkdc<sup>scid</sup>* mice (females, six weeks old) were purchased from Jackson Labs (Bar Harbor, ME, USA) for the experiment of testing BMMSC transplantation into immunocompromised mice.

For testing of drug Atezolizumab, 8-week-old female C3H/HeJ mice were purchased from Jackson Labs (Bar Harbor, ME, USA). After dividing mice to two groups of n=5. The ovariectomy procedure was performed mice also using an electrocautery machine. A Two-weeks period was allowed for the OVX phenotype to be properly established, after two weeks the injection of GMSCs was infused into both groups, The drug group further received a systemic injection of Atezolizumab anti-PDL1 drug obtained from Invivogen USA (#hpd11-mab9) 80mcg of drug was administered, and the placebo received PBS. Two weeks after the drug group had an additional 40mcg of drug administered to insure the maintenance of the effect. all mice were sacrificed at 4 weeks post-injection for subsequent examination.

#### **Isolation and preparation of mouse GMSCs:**

Adult mice were used to harvest gingival tissue. A single suspension of gingival tissue was processed for all nuclear cells (ANCs,  $15 \times 10^6$ ) from mice gingiva was seeded in 10 cm culture dishes (Genesee) then incubated at 37 °C with 5% CO<sub>2</sub>. After 48 hours, non-adherent cells were removed, and adherent cells were cultured for additional 14 days in alpha minimum essential medium (α-MEM, Invitrogen)

supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine (Invitrogen), 55  $\mu$ M 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin (Invitrogen). Passage one and two mouse GMSCs were used in for cell infusion. GMSCs were tested for common MSC markers CD90 CD105, and SCA-1 as shown in Fig.5. Cells were prepared for infusion and ( $2 \times 10^5$ ) cells were prepared in sterile 200  $\mu$ l phosphorus buffered saline (PBS) for each mouse and injected as an infusion systemically via the tail vein.



**Figure 5. GMSC's expression of common MSC markers.** Immunostaining images showing the expression of common MSC markers CD90, CD105, and SCA-1 by GMSCs, these markers are amongst methods used to identify Mesenchymal stem cells. Scale bar, 50  $\mu$ m.

#### **Computed Microtomography and analysis of datasets:**

To analyze the Bone Mineral Density (BMD) and Total Bone Volume (BV/TV). The femurs and mandibles of mice were harvested at sacrifice then fixed in 4% paraformaldehyde solution, femurs were then scanned using a desktop high-resolution Scanco  $\mu$ CT35 scanner (Scanco Medical AG, Bruttisellen, Switzerland). The scanning of specimens was standardized to a measurement voxel size of 20  $\mu$ m at 70kVp and 200  $\mu$ A. Datasets were reconstructed, and images were analyzed using the system-provided by the manufacturer (Scanco Medical). Values were obtained for BMD, and total bone volume.

#### **Histological and histomorphometry analysis:**

Femurs and mandibles were fixed in 4% paraformaldehyde for 48 hours then decalcified with 10% EDTA (pH 7.4) for three weeks undergoing a twice-weekly change of EDTA to maintain the exposure of femurs to 7.4 pH levels. Following decalcification, paraffin embedding was completed, then ten  $\mu$ m thick sections were produced using a microtome and prepared for staining. The first stain selected for both mandibles and femurs, was the Hematoxylin and Eosin (H&E)

stain in order to quantify the trabecular bone percentage in the distal metaphyseal region of the femurs, as well as the retromolar area distal to M3 in the mandibles. Results are reported in the form of trabecular bone percentage in relation to the total standardized area of interest (%/area). Further testing for femurs alone includes Tartrate-resistant acid phosphate (TRAP) staining assay to label TRAP+ cells. TRAP staining kit was purchased from (Sigma-Aldrich), and samples were prepared by deparaffination then stained according to manufacturer instructions. TRAP staining images were also acquired from the distal metaphyseal region of the femur. The results are shown as the number of osteoclasts per square millimeter of bone surface area (N.Oc/BS). For dynamic bone histomorphometry, double calcein labeling was utilized, the mice were intraperitoneally injected with calcein (Sigma, 15 mg/Kg body weight) which was prepared in 2% sodium bicarbonate solution at two intervals 13 and 3 days before sacrifice. After sacrifice, femurs were fixed in 4% paraformaldehyde for 48 hours then decalcified with 10% EDTA (pH 7.4) for a period of two weeks and samples were prepared for cryo-sectioning and slides were created and mounted with fluoroshield mounting medium with DAPI (Ab 104139) and pictures were obtained for the bone dynamic histomorphometry analyses for MAR. Mineral apposition rate is the distance measured between the two labels divided by the time between the two IP injections.

### **In vivo Oil red O staining / Fatty marrow analysis:**

For the analysis of adipocytes surrounding the trabecular areas of the metaphyseal region of femurs, they were fixed in 4% paraformaldehyde and decalcified with 10% EDTA (pH 7.4) for a period of two weeks. After that, femurs were prepared for cryo-sectioning by processing the samples in 15% sucrose in 3 hours, then 30% sucrose overnight. The following day, samples were embedded in 1:1 OCT and 30% Sucrose for 3 hours, then moved and embedded into OCT solution and stored in -20 °C. Freezing microtome machine was then used to create 12 Micrometer sections. The staining of sections was then completed using the Oil Red-O solution. Positive areas were quantified under the microscope and illustrated as a percentage of the total area.

### **Enzyme Linked Immunosorbent Assay (ELISA):**

In order to determine the blood serum levels of the different markers, IFN- $\gamma$ , IL-17, ALP, and RANKL, peripheral blood was collected at sacrifice, and the serum was extracted from blood samples by letting the blood samples sit for one hour then undergoing the centrifugation process to complete the serum extraction. Samples were then stored in -20 °C until testing was performed. For ELISA testing, mouse ELISA MAX™ Deluxe kits for IFN- $\gamma$ , IL-17, and RANKL were purchased from (BioLegend), ALP was purchased from G-biosciences (IT5507), and ELISA testing was performed according to the manufacturer's instructions for each assay. Results are shown as levels of markers present in serum in picogram/milliliter.

### **Isolation and culture of mouse BMMSCs.**

Harvesting of single suspension of bone marrow-derived all nuclear cells (ANCs) from femurs was completed after sacrifice, and  $15 \times 10^6$  cells were seeded in 10 cm culture dishes (Genesee) then incubated at 37°C with 5% CO<sub>2</sub>. After 48 hours, dishes were washed with PBS to remove any non-adherent cells. Adherent cells were cultured for additional 14 days in alpha minimum essential medium ( $\alpha$ -MEM, Invitrogen) supplemented with 20% fetal bovine serum (FBS), two mM L-glutamine (Invitrogen), 55  $\mu$ M 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin with 100  $\mu$ g/ml streptomycin (Invitrogen). Cells were incubated until experiments were performed using Passage one and two mouse BMMSCs.

### **Transplantation of BMMSCs into immunocompromised mice.**

After the sacrifice of mice, around  $4.0 \times 10^6$  mouse BMMSCs from OVX, GMSC-treated, and control mice were incorporated with 40 mg of hydroxyapatite/tricalcium phosphate (HA/TCP) powder (Zimmer Inc., Warsaw, IN, USA) and subsequently implanted subcutaneously into the dorsal surfaces of eight-week-old female immunocompromised Prkdcscid mice. The implants were implanted for a period of twelve-weeks, then mice were sacrificed, and transplants were harvested. After that, they were fixed in 4% paraformaldehyde then decalcified with 10% EDTA (pH 8.0) for two weeks in preparation for paraffin embedding. Ten  $\mu$ M paraffin sections of the transplants were then created using a microtome, then deparaffinized, rehydrated, and stained with the hematoxylin and



eosin (H&E) stain. Results are shown as a proportion of the bone formed to the total area (Bone/total area).

#### **Proliferation capacity analysis / BrdU labeling assay.**

BMMSCs were seeded into 8-well chamber slides (Thermo Scientific) with a concentration of  $2 \times 10^4$  per well. After two days of cell culture, A concentration of (1:100) BrdU labeling reagent (Invitrogen) was added to the medium, after which the cells were incubated at 37°C with 5% CO<sub>2</sub> for 24 hours. Cells were then fixed with 70% Ethanol, denatured with 2N HCl, and stained with anti-BrdU antibody (Invitrogen) overnight at 4°C. The second antibody was incubated at room temperature for 1 hour, then mounted and counterstained with fluoroshield mounting medium with DAPI (Ab 104139). The positive cells from four fields per sample were quantified under microscopy and presented relative to the total number of cells. (positive/total cells).

#### **In-vitro osteogenic differentiation capacity analysis.**

The culture of BMMSCs was done under osteogenic inductive conditions with a twice/week change of the medium. The growth medium composed of 2 mM  $\beta$ -glycerophosphate (Sigma-Aldrich), 100  $\mu$ M L-ascorbic acid 2-phosphate (Wako), and 10 nM dexamethasone (Sigma-Aldrich). After four weeks of osteogenic

induction, matrix mineralization was detected by 1% Alizarin Red (Sigma-Aldrich) staining or cells of other wells were lysed for protein isolation and examination of osteogenic gene expression. For Mineralized nodule formation, stained positive areas were quantified using NIH ImageJ software and shown as a percentage of the total area (%/Total area).

#### **In-vitro adipogenic differentiation capacity analysis.**

BMMSCs were cultured under adipogenic inductive conditions. The adipogenic medium contained 500 nM isobutyl methylxanthine (Sigma-Aldrich), 60  $\mu$ M indomethacin (Sigma-Aldrich), 500 nM hydrocortisone (Sigma-Aldrich), 10  $\mu$ g/ml insulin (Sigma-Aldrich), and 100 nM L-ascorbic acid phosphate. Eight days after adipogenic induction, wells were stained with Oil-red-O stain (Sigma-Aldrich) for quantification of adipocytes, and positive cells were counted under a microscope and shown as a percentage of the total cells (%/total number of cells). Additional good sets were also lysed for protein collection in order to examine adipogenic gene expressions.

#### **Western immunoblotting.**

After cells are washed using PBS and lysed in the RIPA lysis buffer system with protease and phosphatase inhibitors (Santa Cruz). Protein levels were then quantified using Pierce™ BCA Protein Assay Kit (Thermo scientific). 20  $\mu$ g of

proteins were separated by SDS-PAGE (Invitrogen) and transferred to 0.2  $\mu$ m nitrocellulose membranes (Millipore). Then the membranes were blocked using a 5% non-fat dry milk and 0.1% Tween-20 for a period of one hour, followed by overnight incubation with primary antibodies diluted in blocking solution. Antibody to PPAR $\gamma$  (sc-7196) was purchased from Santa Cruz Biotechnology, Inc. Antibody to LPL (PA5-47033) was purchased from Thermo Fisher Scientific. Antibodies to RUNX2 (12556) were obtained from Cell Signaling Technology. Antibodies to ALP (ab108337) was purchased from Abcam, and  $\beta$ -Actin (A5441) were purchased from Sigma-Aldrich. The membranes were then washed and incubated for one hour in HRP-conjugated secondary antibody (Santa Cruz) diluted in blocking solution. Immunoreactive proteins were detected using SuperSignal<sup>™</sup> West Pico PLUS Chemiluminescent Substrate, SuperSignal<sup>™</sup> West Femto Maximum Sensitivity Substrate (Thermo) and Autoradiography Film (Labscientific, inc).

### **Flow Cytometry.**

After mice were sacrificed, T-cells were collected from spleens. T cells were extracted by processing spleens and treating them with ACK buffer for red blood cells removal (Lonza, Switzerland), after that isolated T-cells were incubated for an hour on ice with 1 $\mu$ g/100 $\mu$ l of PerCP anti-mouse CD4 Antibody (100538, BioLegend), then for the T-reg testing, an additional 2  $\mu$ g of APC anti-mouse CD25 (102012, BioLegend) was added as well. FoxP3 staining buffer kit was used to fix and permeabilize the samples overnight using Intracellular Staining

Permeabilization Wash Buffer (BioLegend). Cells were then stained with 2ug of either PE anti-mouse FoxP3 (320008, BioLegend) for T-regs, or with APC anti-mouse IFN- $\gamma$  for Th1 (505810, BioLegend) for 30 minutes in the dark at room temperature. Then washing with FACS buffer was carried out. After that, all samples were analyzed using FACSCalibur with CellQuest software (BD Bioscience).

### **Immunofluorescent microscopy.**

To test the GMSCs expression of MSC markers CD90, CD 105, and SCA-1. The anti-mouse CD-90 antibody was obtained from Abcam (ab3105), anti-mouse CD 105 antibody was obtained from BD Biosciences (550546), and anti-mouse SCA-1 antibody was also obtained from BD Biosciences (553334). For immunostaining of PD-L1 expression. PD-L1 antibody (#MA5-29672) was obtained from ThermoFisher Scientific. The samples were then incubated with the obtained specific or isotype-matched first antibodies (1: 200) overnight at 4 °C, and then the next day stained with the second antibody according to the manufacturer's instructions. Slides were mounted using Fluoroshield Mounting Medium with DAPI (Abcam). Pictures are shown for illustration purposes.

### **siRNA transfection.**

For mechanistic testing, an additional treatment group of OVX mice treated with PDL-1 knockdown GMSCs was assigned and In vitro siRNA was performed, GMSCs ( $0.8 \times 10^6$ ) were seeded in 60 mm culture dishes and treated with Pdccl-1L1 siRNA (SC-39700, Santa Cruz) or vehicle siRNA control (Santa Cruz) with lipofectamine reagent (Invitrogen), according to the manufacturers' instructions. After successful transfection was achieved, and the protein expression level is verified with western immunoblotting, siPdl1 cells were collected and used for infusion into the siPdl1 mice group.

### **T-cell apoptosis assay**

GMSCs or siPdl1 GMSCs ( $0.2 \times 10^6$ ) were seeded in a 24-well culture plate (Corning) containing Dulbecco's Modified Eagle's Medium (DMEM; Lonza, Basel, Switzerland) with 10% heat-inactivated FBS, 50  $\mu$ M 2-mercaptoethanol, 10 mM HEPES, 1 mM sodium pyruvate (Sigma-Aldrich), 1% non-essential amino acid (Cambrex, East Rutherford, NY, USA), 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. After incubation of GMSCs for 24 h, Spleens from wildtype were harvested and processed ACK buffer for red blood cell removal (Lonza, Switzerland) and extraction of T-cells. After isolation of T-cells, ( $1 \times 10^6$ ) T-lymphocytes were pre-stimulated by seeding them in anti-mouse-CD3 $\epsilon$  (100331, BioLegend) antibody with a concentration of 5  $\mu$ g/mL and soluble anti-mouse-CD28 (122004, BioLegend) antibody with a concentration of 2  $\mu$ g/mL. After 2-3

days of T-Cell activation and confirming aggregation and growing was achieved. T-Cells were then directly loaded onto WT GMSCs or siPDL1 GMSCs and co-cultured for three additional days. Additional wells for control contained plated T-cells only in medium with no cells. After that, apoptotic T-cells were detected by staining with a CD3 antibody, followed by the use of the Annexin-V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) and then samples were run and analyzed by the use of a FACSCalibur flow cytometer equipped with CellQuest software.

### **Statistics:**

All the data we have shown were expressed as the mean  $\pm$  SEM. Statistics were performed using the software SPSS V.26. (IBM corporation. Armonk, New York) Comparisons between two groups were analyzed using the independent two-tailed Student's t-tests. As for the comparison between > two groups were analyzed in IBM SPSS V.26 using one-way ANOVA/Fisher LSD. P-values less than 0.05 were considered statistically significant.


# Results

## **A single infusion of GMSCs successfully improved the bone phenotype of the ovariectomized mouse model**



To explore the therapeutic effects of a GMSC transplantation on the OVX mouse, an OVX disease model for treatment was established. The timeline of the treatment consisted of obtaining 8-week-old mice from Jackson labs, the mice would be then assigned to 3 different groups. After allowing mice to acclimate into their groups for a week. An ovariectomy procedure would be completed to 2/3 groups, the OVX group and the GMSC-treatment group. Mice would then be allowed a period of two weeks for the osteoporosis associated with ovariectomy to develop. After two weeks the GMSC treatment group would receive a single GMSC transplantation. After 4 weeks of the transplantation, all mice would be sacrificed for experimentation purposes. The computed microtomography analysis of mice femurs (Fig.6) revealed a significant deterioration in the bone phenotype of the OVX mice in comparison to the negative control group as shown by a decrease in the measurements of bone mineral density (BMD), total bone volume (BV/TV), Connectivity density (Conn.D) as well as an increase in Structure Model Index (SMI) values. This reported effect validates the OVX osteoporosis model and provides additional assurance of the validity and the effect of ovaries removal on bone. On the other hand, our group of interest, the GMSC-treatment group showed



that a one-time GMSC transplantation intravenously produced a marked improvement in the bone phenotype of mice femurs as seen by the elevation in the bone BMD, total bone volume, Conn.D values, as well as the decrease in SMI values.

**A**












**Figure 6. Computed microtomography analysis of femurs. (A)** Images from the scanned femurs showing difference in trabeculation between different groups. **(B)** Bone mineral density measurements revealing improved bone phenotype in GMSC-treatment group in comparison with OVX group. **(C)** Total bone volume measurement also showing an improvement in the GMSC-treatment group when compared with OVX. **(D)** Conn.D measurement values of different groups. **(E)** SMI measurements of study groups.

To further investigate the effects of ovariectomy and GMSC treatment of the bone phenotype in the femurs. Histological analysis of the femurs was completed to analyze the trabeculation levels of distal metaphyseal regions. Our H&E analysis indicated a similar outcome and mirrored the finding of computed microtomography of significant improvement in the distal femur trabeculation which is seen the GMSC group when compared with the OVX group (Fig.7).




**Figure 7. Histological analysis of femurs.** H&E staining of distal femoral metaphyseal region showing less trabeculation levels of the ovariectomized group in comparison to both the control and GMSCs-treated group. Scale bar, 500  $\mu$ m.

To test whether the osteoclastic activity would be evaluated in bone of those mice, we further examined the effect of GMSCs transplantation on the number of osteoclasts in femurs collected from study groups, we found that the number of osteoclasts is markedly reduced in the control group when compared to the ovariectomized mice, this reduction of osteoclast number is also seen after the GMSCs transplantation, this was tested through the observed decrease in number of Tartrate-Resistant Acid Phosphatase positive cells (TRAP) (Fig.8).




**Figure 8. Trap<sup>+</sup> cells analysis of femurs.** Trap<sup>+</sup> cells staining shows a significant increase in Trap<sup>+</sup> cells in the ovariectomized mice group in comparison to both the control and GMSCs-treated groups. Scale bar, 100  $\mu$ m

To further test whether there was fatty marrow presence in femurs, Oil red O staining was utilized for this test. Our results reveal the presence of higher Fatty marrow levels in the femurs of the OVX group in comparison with the control group. The GMSCs-treated group femurs show a significantly reduced fatty marrow area in comparison to OVX group (Fig.9). We then moved to measure the bone formation rate in femurs by performing a calcein double labeling assay aimed at determining the daily rate of bone formation, we found that the control group had the highest bone formation rate as indicated by the double labeling of calcein, the OVX group on the other hand showed the lowest mineral apposition and GMSCs-treated group showed a significantly higher level of MAR than OVX group (Fig.10).




**Figure 9. Oil-Red-O staining/in-vivo analysis of fatty marrow.** Fatty marrow levels as tested by Oil-Red-O staining show an increase in the levels in the OVX group when compared with the control group. The fatty marrow level is also reduced in the GMSCs-treated group when compared to the OVX group. Scale bar, 100  $\mu$ m.






**Figure 10. Dynamic bone histomorphometry.** The mineral apposition rate was tested by calcein double labeling showing an increased MAR in control and GMSC-treatment groups when compared with the OVX group. Scale bar, 50  $\mu\text{m}$ .


After testing the effect of transplantation on the femurs of mice, we next explored the effect of OVX and GMSCs transplant in the mandibles of mice. The computed microtomography scans and analysis of the retromolar area distal to M3 in mice mandibles revealed a significant decrease in the bone phenotype of the OVX mice in comparison to the control group as shown by a decrease in the measurements of BMD and BV/TV mirroring the effect seen in femurs. The GMSC-treatment group as well showed a marked improvement in the bone phenotype of the mice mandibular jawbone when compared to the OVX group (Fig.11 A-C). This is further confirmed by H&E stain and the analysis of the trabeculation levels in retromolar area of mandibles showing the same trend as the one seen in the computed microtomography (Fig.12).






**Figure 11. Computed microtomography analysis of mandibles. (A)** Images from the scanned mandibles showing difference in trabeculation between different groups. **(B)** Bone mineral density measurements revealing improved bone




phenotype reflected in GMSC-treatment group mandibles in comparison with OVX group. **(C)** Total bone volume measurement also shows an improvement in the GMSC-treatment group when compared with OVX.



**Figure 12. Histological analysis of mandibles.** H&E staining of retromolar area of M3 showing less trabeculation levels of the ovariectomized group in comparison to both the control and GMSCs-treated group. Scale bar, 500  $\mu$ m.

We next explored the effect of the transplantation on blood serum levels of different inflammatory and osteoclast markers. We saw that levels of Serum IFN-  $\gamma$ , and IL-17 is markedly decreased in the GMSC treated group compared to the OVX group which is in turn significantly higher in expression when compared to the control group mice (Fig 13.A, B). Osteoclast marker RANKL was also significantly decreased in the GMSC treated group (Fig 13.C). These Elisa results suggest that GMSC infusion successfully reduced the inflammation in the ovariectomized mice and downregulated the osteoclastic activity. Additionally, Serum ALP levels were measured in the blood of mice after sacrifice and show a similar trend of a marked increase in serum ALP in those mice of the OVX group when compared to the control group, the level of ALP was seen less in the GMSCs-treated group than OVX but this decrease is not of significance (Fig 13.D).





**Figure 13. Blood serum markers analysis.** (A). IFN- $\gamma$  levels were overly expressed in the serum of OVX mice as seen by the Elisa testing, the control group possessed the lowest levels of IFN- $\gamma$  expression, and GMSCs treatment significantly reduced the expression versus the OVX group. (B). IL-17 level was expressed at about 100pg/ml in the ovariectomized mice blood serum, this was significantly less in the control group and the GMSCs treatment significantly reduced the expression level compared to OVX group. (C). RANKL blood serum levels in the OVX mice was almost double the level found in the control mice blood, and the GMSCs treatment reduced the blood serum level of RANKL. (D). ALP levels in blood serum tested showing a significant increase of ALP expression in serum of OVX mice when compared with the control mice, ALP is mildly decreased in GMSCs treated mice when compared to OVX mice.


**GMSCs transplantation into OVX mice rescued the function of the endogenous population of BMMSCs.**

After addressing our first aim of the study where It was hypothesized that the ovariectomy would lead to significant bone loss and that the single transplantation of GMSCs would improve that osteoporotic bone phenotype. Next we hypothesized that the GMSCs transplantation into the OVX mice would improve the function of the endogenous population of BMMSCs. This part of the study aimed at examining the effects of OVX on the BMMSCs of mice and how GMSCs transplantation influences that effect. To run functionality measuring in-vitro experiments, the collection of mice BMMSCs from the three different groups was

completed after sacrifice at 15 weeks. Several experiments were performed in order to form a generalized idea about the functional capacity of BMMSCs and what would a transplantation achieve. This included analyzing the ability of harvested cells to form Colony forming unit-Fibroblasts (CFU-F) by performing a CFU-F assay, measure the ability of the cells to proliferate utilizing a cell proliferation assay, testing their adipogenic differentiation capacity with the measurement of their expression levels of adipogenic proteins Lipoprotein Lipase (LPL) Peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ), testing of their osteogenic differentiation capacity with the measurement of their expression levels of osteogenic proteins Runt-related transcription factor 2 (RUNX2), Alkaline Phosphatase (ALP), and finally by further testing the ability of BMMSCs harvested from mice to form new bone by transplanting them into immunocpromised mice after being mixed with particulate ceramic scaffold.

First test after harvesting the BMMSCs from mice, a simple experiment was completed to determine the ability of the cells harvested to form colonies. A CFU-F assay was completed to examine the formation of colonies. While there is no significant difference observed in the abilities of different groups, the BMMSCs harvested from the OVX group showed the highest number of colonies formed, and while the negative control group showed the lowest ability to form colonies, the GMSCs group lies in between both groups in terms of ability to form colonies as shown in (Fig.14).






**Figure 14. CFU-F Assay.** Analysis of colony formation abilities of cells from different groups shows OVX possess the highest capacity of CFU-F.


After verifying the ability and measuring the capacity of BMMSCs to form CFU-F's as do MSCs, we examined the proliferation capacity of mouse BMMSCs trying to measure their division and doubling abilities. We saw that cells from the OVX group had a significantly higher proliferation rate as shown by an increase in BRDU-positive-cells, this elevation in proliferation capacity is not seen in the

GMSC-treated group as it was of reduced proliferation compared to OVX and at an almost comparable rate to those of the control group (Fig 15).




**Figure 15. BrdU proliferation assay.** Analysis of proliferation capacity of cells from different groups shows BMMSCs from GMSC-treated mice has a proliferation rate comparable to the control while the BMMSCs from OVX mice showed the highest proliferation rate. Scale bar 50  $\mu$ m.

In the testing of osteogenic differentiation potential of BMMSCs. The OVX group showed a significant reduction in osteogenic differentiation capacity, while the GMSC-treated group showed a significantly higher potential as shown by the mineralized nodules formation evaluated by Alizarin red staining (Fig.16), the decrease in OVX osteogenic potential is accompanied by a decrease of Runx2 and ALP expression, On the other hand an increase in the expression is seen in both GMSC-treated and control groups as assessed by western blot analysis (Fig.17).




**Figure 16. Osteogenic differentiation capacity assay.** Osteogenic differentiation capacity of cells from different groups shows BMMSCs from GMSC-

treated mice has a markedly higher osteogenic differentiation capacity than the BMMSCs from OVX mice.




**Figure 17. Osteogenic proteins expression levels.** Protein level analysis reveal that levels of RUNX2 and ALP proteins are expressed at higher levels in the BMMSCs from GMSCs-treated mice when being exposed to osteogenic inductive conditions, whereas those from OVX group express the same proteins at significantly less level.

Furthermore, when finished testing the osteogenic differentiation capacity, the adipogenic differentiation potential of BMMSCs was also evaluated after inducing the cells and staining them with Oil-red-O staining, the BMMSCs of OVX group mice showed a significantly higher adipogenic differentiation potential when compared with BMMSCs from both the control and GMSC-treated groups (Fig 18). This was also further verified by the observed increase in the levels of the adipogenic proteins PPAR-G and LPL in the OVX group. These proteins were expressed by BMMSCs from control and GMSC-treated mice as well but at a significantly reduced level (Fig 19).




**Figure 18. Adipogenic differentiation capacity assay.** Adipogenic differentiation capacity of cells from different groups shows BMMSCs from OVX mice having a markedly higher potential for adipogenic differentiation than those from BMMSCs of control or GMSC-treated mice. Scale bar 50  $\mu$ m.



**Figure 19. Adipogenic proteins expression levels.** Protein level analysis reveal that levels of LPL and PPAR-  $\gamma$  proteins are expressed at significantly higher levels in the BMMSCs from OVX mice when being exposed to adipogenic inductive conditions, whereas those from both GMSC-treated and control groups express the same proteins at significantly less level.

In the last part of determining the influence of OVX and GMSC treatment on the function of BMMSCs, we wanted to test the abilities of BMMSCs from our groups to form new bone in vivo. The test involved using immunocompromised mice and the implantation of BMMSCs from test groups to determine their bone formation rates after incorporating them into HA/TCP grafts. When analyzed, grafts from GMSCs-treated and control group exhibited significantly higher level of new bone formation in comparison to OVX groups (Fig.20).



**Figure 20. In-vivo bone formation capacity assay.** Testing of the bone formation capacity revealed higher bone formation observed in those BMMSCs from control

and GMSC-treated mice, grafts containing BMMSCs from OVX mice show a severe deficiency in the ability to form new bone. Scale bar, 20  $\mu$ m.


These results and findings of our functional testing involving BMMSCs of study groups suggest that the endogenous BMMSs population harvested from the OVX mice group were of significantly compromised function in all the experiments completed in this part. This function is of normal expected levels in the mice of the control group. The BMMSCs from the GMSCs-treated mice revealed there was and significant improvement in function and the BMMSCs were rescued as a result of the GMSC transplantation.



## **Mechanistic Investigation**


### **GMSCs effect in the OVX mouse model is independent of Fas/FasL cell death pathway**


To test the mechanism behind GMSCs effect in the OVX mouse model. First, we tested a potentially involved pathway. New groups to test FASL/FAS pathway are shown in (Fig.21).



**Figure 21. FAS/FASL pathway testing group assignment.** (1) Mice not undergoing ovariectomy procedure, nor transplantation. (2) Mice undergoing ovariectomy procedure, but no cellular transplantation. (3) Mice undergoing ovariectomy procedure, then a single transplantation of GMSC. (4) Mice undergoing ovariectomy procedure, then 1X transplantation of FAS deficient GMSC obtained from LPR mice (5) Mice undergoing ovariectomy procedure, then 1X transplantation of FASL deficient GMSC from obtained GLD mice.


Following the same outline as previously describe in Fig.4 and after the experiment concluded and mice were sacrificed, new femurs were scanned and analyzed. the compute microtomography images and analysis also revealed a significant deterioration in the bone phenotype of the OVX mice in comparison to the negative control group as shown by a decrease in the measurements of bone mineral density (BMD), total bone volume (BV/TV). While a GMSCs treatment improved the bone phenotype in the OVX mice, so did Fas<sup>-/-</sup> and FasL<sup>-/-</sup> GMSCs (Fig.22).






**Figure 22. Computed microtomography analysis of *Fas*<sup>-/-</sup>, *FasL*<sup>-/-</sup> GMSCs treatment.** Femurs of *Fas*<sup>-/-</sup>, *FasL*<sup>-/-</sup> GMSCs show similar effect in BMD and BV/TV values as that observed as an improvement of the phenotype of the femurs of GMSC-treatment group.


Additional analysis of femurs further revealed that the trabeculation levels of those from mice treated with Fas<sup>-/-</sup>, and FasL<sup>-/-</sup> GMSCs are similar to those treated with wild type GMSCs (Fig.23) as shown by H&E analysis of the sections created.





**Figure 23. Histological analysis of femurs.** Fas<sup>-/-</sup>, FasL<sup>-/-</sup> GMSC treated mice showing an improvement in the trabeculation levels of femurs compared to the femurs of GMSC-treatment group. Scale bar, 500  $\mu$ m

This was further confirmed with TRAP+ cell testing to quantify the number of osteoclasts in the distal metaphyseal region, we found that TRAP+ cell numbers are in agreement with the previous finding of trabeculation levels in H&E sections of Femurs as those of Fas<sup>-/-</sup>, FasL<sup>-/-</sup> GMSCs-treatment show a similar level of TRAP+ cells as WT GMSCs-treated group (Fig.24).




**Figure 24. TRAP<sup>+</sup> cell analysis of femurs.** Femurs of Fas<sup>-/-</sup>, FasL<sup>-/-</sup> GMSCs treated mice show similar levels of osteoclasts to those of the femurs of GMSC-treatment group. Scale bar, 100  $\mu$ m.



The testing of Fas/FasL deficient GMSCs on the bone phenotype showed a similar effect as the one seen in treatment of mice by wild type GMSCs. This indicates that GMSCs-mediated effect in the OVX mouse is independent of Fas/FasL pathway. The next pathway investigated as a pathway to play a potential role is a similar pathway called PD-1/PD-L1 pathway.


### **GMSCs influences T-cells in the OVX mice via the PD1/PDL1 pathway**

Programmed death-1 (PD-1) is a protein first described by Ishida; it is a member of the immunoglobulin gene superfamily and plays a role in cell death by apoptosis (67). PD1 is known to be expressed by T-cells, B cells, as well as other types of cells. PD1/PDL1 pathways application has been investigated in infections, cancer therapies and immunotherapies due to its role in immune regulation (68,69). Investigations of PD-1/PD-L1 pathway show that PD-1 ligation restored immune tolerance potentially by the suppression of T-cells, inducing their apoptosis as well as its promotion of T-reg function (70,71) MSCs are also known to express PD-L1 and induce T-cell suppression via the PDL1/PD1 pathway accentuating the importance of PD-L1 in MSC mediated immunoregulation (72). This prompted us to propose that PD-L1/PD-1 pathway is of a significant role in GMSCs immune-mediated effect in the OVX mice and that GMSCs are directly influencing activated T-cells leading to their apoptosis (Fig.25). To test and confirm this we formulated four study groups to examine our theory of PD-1/PD-L1's pathway involvement (Fig.26).



**Figure 25. Proposed mechanism involving GMSCs suppression of T-cells.**

GMSCs interact with T-Cell via PD-1/PD-L1 pathway and induced T-cell apoptosis.






**Figure 26. Study groups of PD-1/PD-L1 pathway mechanistic investigation.**

(1) Mice not receiving ovariectomy, nor transplantation. (2) Mice receiving ovariectomy but without cellular transplantation. (3) Mice receiving ovariectomy procedure and a single transplantation of WT GMSC. (4) Mice receiving ovariectomy and a single transplantation siPDL1 GMSCs.


To verify the knockdown of PD-L1 gene in GMSCs after using siRNA approach to reduce its expression, protein was analyzed to detect the level of protein expression (Fig 27).



**Figure.27 Expression levels of PD-L1 protein.** Verification of protein levels after utilization of siRNA approach to the knockdown the expression of PD-L1.


To further verify the successful knockdown, we attempted to test the expression of the protein utilizing an immunohistochemistry approach to stain and we saw higher


levels of siPd11 in the WT GMSCs (Fig 28). After that we used either GMSC or siPDL1 GMSC to transplant into the OVX mice with same previously followed timeline (Fig.4), that included sacrifice of mice after 15 weeks for further analysis.



**Figure.28 Immunohistochemistry analysis of PD-L1/MSc markers expression levels.** PD-L1 protein appears to be expressed at lower rate as seen by the decreased density in PD-L1 signal in siPd11 knockdown GMSCs in comparison to that in WT GMSCs. Scale bar, 50  $\mu$ m.

After testing whether GMSCs do express PD-L1 and successfully knocking down its expression, it was then used in treatment. After sacrifice, the femurs from mice were scanned and analyzed. We saw that siPd11-GMSCs failed to improve the trabecular bone phenotype in the OVX mice in comparison to the WT-GMSC treated group as shown by the  $\mu$ CT scan and analysis the measurements BMD, as well as BV/TV (Fig.29).






**Figure.29 Computed microtomography analysis of siPd11 GMSCs treatment.**


Analysis of femurs from siPd11-GMSC treated mice have a marked deficiency in the trabeculation of the distal metaphysis region just as seen in OVX mice whereas the WT GMSCs-treated group show a marked improvement.


In addition to the scans of femurs, Histological analysis was also carried to verify the trabeculation levels of the distal metaphyseal region. We saw that the trabeculation in femurs from siPDL1-GMSCs group is significantly compromised just like those from the OVX mice when compared with those from the GMSCs treated group (Fig.30).



**Figure.30 H&E analysis of femurs.** Trabeculation levels shown to be severely compromised in the siPd11-GMSC treated femurs in comparison to WT GMSCs treated ones, they are further comparable to the femurs from the OVX group. Scale bar, 500  $\mu$ m.

Because the trabeculation levels are compromised in the siPd11-GMSC-treated femurs, we would expect the osteoclasts to be higher in number in synergy with it. High osteoclast levels per square millimeter of areas analyzed in femurs lead us to confirm the defect of siPd11-GMSCs by their failure to reduce TRAP+ cells in the femurs (Fig.31).






**Figure.31 TRAP+ cell analysis.** TRAP+ cells are of increased numbers in analyzed areas of femurs from siPdl1-GMSCs treated mice, as well as those from the OVX group. Scale bar, 100  $\mu$ m.

Additionally, to test the levels of adipocytes that is associated with osteoporosis in femurs and the increased risk of fractures. An in-vivo test of the levels of fatty marrow in the distal metaphyseal region of femurs was completed. Femurs of siPDL1-GMSCs treated group showed a higher level of fatty marrow as show by increased levels by Oil Red O positive areas. This increased level of fatty marrow is also seen in the OVX treated group. GMSC-treated group femurs showed a significantly lower levels that are comparable to the control group (Fig.32).






**Figure 32. in-vivo femur fatty marrow analysis.** An increase in fatty marrow seen siPd11-GMSCs treated mice similar to those of OVX treated mice. Scale bar, 500  $\mu$ m.




### **Testing of an Anti-PD-L1 drug therapy in combination with GMSCs infusion of OVX mice.**




After confirming the failure of siPdl1 GMSCs to improve the bone phenotype in the OVX mice, we wanted to verify that PD-L1 is an immune checkpoint for GMSCs-mediated effect seen in the osteoporotic mice. so, we hypothesized that the administration of an anti-PDL1 drug (Atezolizumab) would block the therapeutic effect of the GMSCs transplantation and that there would be no improvement in the bone phenotype after GMSCs treatment. In order for us to test this hypothesis, we utilized two study groups as shown in (Figure.33) and formulated a timeline for our experiment (Figure.34) consisting of a double injection of the drug Atezolizumab in the test group and a placebo in the control group after GMSCs transplantation. After sacrifice, the mice femurs were collected and scanned with Scanco MCT35 scanner and the trabeculation levels are shown in (Fig.35). We also analyzed the BMD of femurs as well as Total bone volume (BV/TV) and we found a statistically significant difference in both values between the control and the test groups. This verifies our hypothesis that the drug treatment of Atezolizumab blocked the therapeutic effect of GMSCs and that PD-L1 is a pivotal immune checkpoint for GMSCs-mediated effect.



**Figure 33. Study groups of PD-L1 drug therapy investigation.** (1) Mice receiving ovariectomy, GMSCs transplantation, and Atezolizumab drug. (2) Mice receiving ovariectomy, GMSCs transplantation, and Placebo (PBS).




**Figure 34. Experimental timeline of treatment.** Ovariectomy procedure done at 9 weeks to designated groups, GMSCs were injected into designated group intravenously via the tail vein.





**Figure.35 Femur Micro-CT images and analysis of Atezolizumab and placebo groups.** Analysis of femurs shows an increased level of trabeculation in the placebo group vs Atezolizumab group as shown in BV/TV and BMD values.

**Testing of GMSCs, siPd11-GMSCs transplantations on subsets of T-cells in the OVX mice model.**

We further tested the immune tolerance levels in the OVX mice treated with GMSCs and effect of GMSCs on the population of T-cells after the completion of the treatment period, We saw that at 4 weeks post-transplantation timepoint the GMSCs treatment had significantly downregulated Th1 and T17 levels in comparison to the levels seen in those of OVX mice. On the other hand, in siPd11-GMSCs treated mice there was a marked increase in Th1 levels in comparison to the WT GMSCs treated mice, while there is still an increase in Th17 as well it wasn't as prominent as Th17. In addition to Th1, and Th17 levels, GMSCs treatment also significantly upregulated T-reg expression in the OVX mice and when testing the expression levels of T-regulatory cells in the siPd11-GMSCs treated mice it was matching to those of the OVX mice confirming the failure of siPd11 GMSCs to influence the expression of T-cells and the success of GMSCs in influencing T-cells in the OVX mouse model (Fig.36).






**Figure 36. Flow cytometry analysis of Th-1, Th-17 and T-reg levels.** Th-1, Th-17 expression and T-reg levels in mice from different groups at sacrifice four-weeks post-transplantation.


**Testing of GMSCs, siPdl1-GMSCs ability of inducing T-cells apoptosis in-vitro.**

In order to examine the effect of GMSCs treatment on the population of T-Cells. We utilized an in vitro approach to test that effect. We harvested T-cells and activated them then cocultured them in vitro with wild type mice GMSCs, or siPDL1 GMSCs. T-Cells were then collected, and an Annexin V apoptosis assay/ flow cytometry analysis was completed. We noted that in after the 3 days of coculture, the apoptosis rate of T-cells only group was almost at 5%. The T-Cells collected from wells cocultured with GMSCs showed an apoptosis rate that is significantly higher at almost 30%, while the T-Cells harvested from the wells where they were cocultured with siPdl1 was significantly lower at around 19%. These findings confirm the ability of GMSCs to induce T-cell apoptosis as well as the finding reported previously that siPdl1 GMSCs are defective and unable to effectively induce T-cell apoptosis (Fig.37).


**T-Cell**



**WT GMSCs**




**siPd11 GMSCs**



7-AAD

Annexin V



**Figure 37. T-cell apoptosis assay.** Coculture of siPd11 and WT GMSCs with T-cells shows a higher ability of WT GMSCs to inducing T-cell apoptosis when cocultured with T-cells than the siPd11 GMSCs.



# Discussion

Osteoporosis is a skeletal system disorder that could occur in all ages at any given population resembling a great worldwide concern. The disease is also of a higher level of concern in particular in those populations of older men, and postmenopausal women as the osteoporosis-related fractures associated with the disease are of tremendous magnitude on healthcare systems. The treatment takes a toll on institutional financial resources. These fractures are also known to be of a higher risk of occurrence in women than in men (1,73,74). For the treatment of the disease, several interventional approaches are available to manage and treat those patients diagnosed with osteoporosis or at risk of developing it. Amongst the available and widely accepted treatment options are either pharmacological or non-pharmacological based treatments. The Non-pharmacological interventions are revolved mainly around dietary and lifestyle modifications such as the increase of calcium or vitamin D intake to achieve peak bone mass in an individuals' growth through life as well as the involvement of exercise routines, these interventions resembling more of a preventive approach and are aimed at reducing the risk of fractures (1).

On the other hand, pharmacologic interventions for diagnosed individuals include the utilization of antiresorptive agents in treatment such as the bisphosphonates class of medications used to reduces bone resorption by mainly increasing the apoptosis rate of osteoclasts (21). Different bisphosphonates class drugs that are used for the treatment of osteoporosis are effective in reducing bone

resorption rates (22-24), but their use has been associated with both short- and long-term adverse effects, with the latter including BRONJ, atypical femur fractures, and concerns of exaggerated suppression of bone turnover rates (25,26,75). Another class of antiresorptive agents available for use are estrogens and selective estrogen receptor modulators (SERMs) (27,28). their use as hormonal replacement therapy in treatment has been associated with reports of breast cancer and cardiovascular events (29,30). The third class of pharmacological, interventional drugs used in the treatment of osteoporosis are anabolic agents, they are different from the mechanism of action used by bisphosphonates as they act on the enhancement of bone formation rather than decreasing the bone resorption rates and an example of anabolic agents is the Parathyroid hormone (PTH). It is a well-known and potent inducer of bone matrix synthesis; it increases osteoblast activation and decreases their apoptosis rates (31). The use of the anabolic agent PTH in treatment of postmenopausal osteoporosis is deemed beneficial but the expense associated with the drug is a limiting factor for its use, in addition to that investigators found there was an incidence of osteosarcoma associated with its use in a two years animal study while testing different variety of doses leading to the recommendation of a limited time use (33,76).

Although the mentioned pharmacologic and non-pharmacologic interventions are currently employed as treatment methods for osteoporosis, the accompanying setbacks with their use could be considered a limitation to the effective utilization of these treatments. This increases the need for the

development of treatment approaches in the field as alternative methods to manage and treat the skeletal system disorder osteoporosis. Systemic infusions and cellular therapy investigations in disease models of chronic nature are of a wider potential for application nowadays; this is shown by the remarkable numbers of clinical trials investigating several diseases in different trial phases ranging from phase I to phase VI clinical trials. The investigations include mainly evaluating the use of MSC cell therapy in different fields like cardiovascular disease, autoimmune disease (i.e., SLE, GVHD, and SS), cutaneous skin defects, bone defects, and liver diseases (42). These present methods of investigation and the advancements of cell therapy applications in the field of research has made the search for a cell therapy-based approach popular. If a cellular infusion is effective therapeutically in the improving the bone phenotype of osteoporosis elevating its mass potentially without the adverse effects associated with those of pharmacological agents, it will lead to opportunities exploring and applying different approaches for treating osteoporosis in addition to a potential in the treatment of various types of immune-related diseases. MSCs in bone research are also deemed popular because of their abilities to directly replace damaged multiple tissues like that of bone, effectively influence cellular mechanisms of recovery, and exert a robust immunoregulatory effect (35,77-79).

In our investigation, the estrogen deficiency-related osteoporosis is an inflammatory disease in nature due to the increase in overall inflammation in the body caused by removal of ovaries or menopause, which is supplemented by an increase in the pro-inflammatory cytokines caused by estrogen deficiency and the

involvement of T-cells that is seen in ovariectomized mice (80-82), this background of the disease along with the immunomodulatory properties and multipotent differentiation potentials of MSCs impelled us to explore the therapeutic and immunomodulatory effects of a dental tissue-derived population of mesenchymal stem cells in a small animal model (OVX) which is a well-established model in bone disease research field (83). While the therapeutic outcome for our cell therapy approach can be investigated as a preventative measure against any OVX associated bone loss, and as a transplantation of SHED has already successfully prevented early phases of bone loss in OVX mice (59), we wanted our experimental timeline for the disease model to allow an adequate period for the defectiveness in the bone to develop. As for the reason we chose to use of GMSCs; they are available after birth, and their application has been explored in multiple disease models previously, and they have proven efficient in the immunomodulation of the host immunologic environment, their effect on the bone phenotype and application in the osteoporotic disease model has not been evaluated. Furthermore, additional reasons we chose to utilize mesenchymal stem cells from the gingiva in our study is that they hold several advantages over other sources of MSCs. They not only possess immunomodulatory properties and multipotent differentiation potential, the procedure of obtaining GMSCs from a source and their harvesting hold less morbidity in comparison to other types of MSCs, and it is high in proliferation.

In our investigation we found that a single systemic infusion of GMSCs was successful in causing a significant improvement in the osteoporotic bone

phenotype caused by estrogen deficiency in the OVX mice, this improvement was seen in the long bones of animals, and it was mainly demonstrated through studying and analyzing the distal metaphyseal region of the femurs as it has been reported to be amongst the commonly used methods to assess bone trabeculation in mice (84). This improvement was also shown in the mandibles of mice as evaluated by measuring and analyzing the retromolar area distal to M3, revealing an improvement in GMSCs treated mice mandibles in comparison to the significantly less trabeculation seen in the OVX mice. In femurs, in addition to our results showing an elevation of bone trabeculation levels of the distal metaphysis of femurs, an increase in the total bone volume, a decrease of the numbers of osteoclasts, a decrease of fatty marrow tissue occurred in femurs, and an increase in the MAR as measured by double calcein labeling, confirming that the overall bone phenotype was improved after the systemic infusion of mice. Mandibles also had a similar effect in the bone trabeculation of the mandibles, as shown by H&E stain and analysis. In addition to the femurs and mandibles analysis showing an improved phenotype, the blood serum analysis of mice showed elevated levels of IFN- $\gamma$ , IL-17, and RANKL in the OVX mice as it was reported that after estrogen deficiency occurs, T-lymphocytes play a role in the bone loss (18,19). This increase was diminished by the infusion of GMSCs which did effectively reduce the level of these serum markers.

Furthermore, there is a deterioration of the endogenous populations of bone marrow stem cells in OVX mice, which contributes to the reduction in bone mineral density (85). Thus, after we confirmed the in-vivo effects of OVX in mice femurs

and mandibles, and we observed the improvement in the phenotype as a result of the GMSCs infusion as well as the reduction seen in some blood serum markers of inflammation, we wanted to investigate further if the deterioration of endogenous BMMSCs in OVX mice would be rescued and their function would be improved in response to the GMSCs infusion by functionally testing those BMMSCs harvested from animals at the end of our timeline. Our first step in testing was to check the colony formation ability of BMMSCs and test their ability to form colonies as well as if there was any difference between the groups, while cells from OVX mice had a slightly non-significant level of higher colonies formed in vitro than those of BMMSCs from other groups, this could be potentially explained that those from OVX mice are higher in colonies formed due to an overactivation or defectiveness of their BMMSCs leading to higher colonies formation. This trend was similar when measuring the proliferation capacities of BMMSCs of groups, OVX mice BMMSCs had a significantly higher level of proliferation, while those from GMSCs-treated mice had a comparable level of proliferation to those seen in the control group. The proliferation rate could be an additional confirmation to our explanation that BMMSCs from OVX mice are in an overactivated stage to compensate for the defectiveness in comparison with those from control and GMSCs-treated mice. Furthermore, BMMSCs are multipotent differentiation potential includes their capacity to be induced to adipogenic, osteogenic, or chondrogenic tissues under certain conditions and are identified as superior in their osteogenic differentiation potential (79,86).

In our study we tested the osteogenic and adipogenic potential of BMMSCs harvested from mice to measure the differentiation potential, we found that those from the control group have the highest osteogenic differentiation potential and the lowest adipogenic potential of all groups, on the other hand, BMMSCs that were harvested from OVX mice had the highest adipogenic differentiation potential and the lowest osteogenic differentiation potential of all groups. This indicates a higher adipogenic tissue formation tendency related to those BMMSCs of the OVX mice and a less capability for osteogenic differentiation. When we looked at BMMSCs from the GMSCs-treated mice, we found that the differentiation potential was comparable to those from the control mice with a higher level of osteogenic differentiation potential than adipogenic differentiation potential. This was further confirmed by analyzing protein expression levels of adipogenic and osteogenic markers of BMMSCs undergoing induction by measuring osteogenic markers ALP, and RUNX2 and adipogenic markers LPL and PPAR-G. Osteogenic markers were expressed in a markedly higher level in BMMSCs from control and GMSCs-treated groups than the OVX group. In agreement with the differentiation capacity, adipogenic markers were highly expressed in BMMSCs from the OVX group, and that expression was seen less in BMMSCs from the control and GMSCs-treated groups. These findings suggest that the functionality of BMMSCs was improved from the GMSCs transplantation and that the defectiveness of BMMSCs caused by the ovariectomy is rescued. In order to further verify the function of BMMSCs was rescued, we tested the in-vivo bone formation ability of BMMSCs harvested from mice through transplanting the cells into dorsal surfaces of immunocompromised

mice after mixing them with HA/TCP. We saw that grafts that were incorporated with BMMSCs from the control or GMSCs-treatment mice had a significantly higher ability to form new bone when compared to those incorporated with BMMSCs from OVX mice, which had a significantly lower level of bone formation. These data showed the rescue of endogenous BMMSCs from the infusion of GMSCs and not only by in-vitro testing of BMMSCs function, but it was also observed in-vivo after grafts incorporated with BMMSCs from GMSCs-treated mice showed a higher level of new bone formation.

After we established the efficacy of GMSCs transplantation and explored the influence they have on improving bone phenotype and the function of the endogenous population of BMMSCs. We wanted to test whether there was an exerted effect of the GMSCs transplantation on the recipients' T-cell population and if the mechanism related to improvement seen by GMSCs transplants is due to its ability to suppress activated T-cells just as its capable of achieving in vitro, as it's already known that the T-cell activity is higher in postmenopausal osteoporosis in both humans and mice, highlighting the role of T-cells in the osteoporotic bone loss caused by estrogen deficiency (63,87,88). Furthermore, when it comes to systemic infusions and stem cell therapies, the mechanisms behind the therapeutic effect and immunomodulation achieved are still in the process of being fully understood. In our study, we established the presence of a positive effect from the GMSCs systemic infusion and further investigated possible pathways involved in the underlying mechanism leading to immune tolerance.



It is reported in the literature that the immunomodulatory properties achieved of a systemic infusion using BMSCs involved the Fas/FasL cell death pathway, and it was revealed that BMSCs expressed both FAS and FASL and that the FAS/FASL pathway is involved in the mechanism behind the BMSCs-mediated therapeutic effect and the induction of T-cell apoptosis which leads to immunologic tolerance (89). For the cells of the body to undergo apoptosis, there are multiple known cell death pathways involved. Fas and FasL, a receptor and its ligand which are members of receptors in the subset of Tumor Necrosis Factor Receptor (TNF-R) superfamily and a part of the FAS/FASL pathway, also known as the CD95-CD95L pathway, and plays a significant role in which the immune system's programmed cell death by apoptosis is initiated achieving homeostasis (90,91). Since FasL is a type II transmembrane protein, the proteins forming as a consequence of its interaction with Fas initiates the Death Inducing Signaling Complex (DISC) (92,93). and because the Fas/FasL pathway is an identified method in BMSCs-mediated induction of T-cell apoptosis and immunomodulatory homeostasis, as previously mentioned (89).

We wanted to investigate the FasL/Fas pathway and whether GMSCs would be similar to BMSCs, and it would be the pathway involved in the GMSCs mediated immunomodulatory effect. To test that, we used gingival tissues from both FAS and FASL deficient mice B6Smn.C3-Faslgld/J and B6.MRL-Faslpr/J to harvest GMSCs for transplantation. We tested the effect of FasL or Fas knockdown GMSCs each separately in-vivo by transplanting them into the OVX mouse following the same previously mentioned experimental timeline (FIG.4). To

our surprise, our results and what we observed as a result of the transplantation after sacrifice was that neither FasL nor Fas knockdown GMSCs had a negative effect as we expected on the bone phenotype and they both had the same therapeutic effect as did the wild type GMSCs in the OVX mice, this was tested in femurs by measuring the BMD, Total bone Volume, bone trabeculation levels, and osteoclasts numbers. What this revealed to us was that GMSCs-mediated effect in the OVX mice was not established through the FAS/FASL pathway as seen in other types of MSCs (i.e. BMMSCs) this could be due to the difference in harvesting source with GMSCs being a type of dental tissue-derived stem cells and may mean they possibly use an alternative cell death pathway in the process of immune regulation or it could be that GMSCs transplantation did not affect the T-cell population of the host at all and the effect was seen in OVX mice is independent of any immune response and solely to the ability of GMSCs to directly differentiate into bone leading to an improvement in the overall bone mass and function of BMMSCs. After testing the Fas/FasL pathway, we looked further in-depth for other potential pathways that may be behind the GMSCs' effect in the OVX mice.

Another pathway we came across involves the PD-1 or programmed cell death one receptor, which is part of the CD28 family, and the PD-1/PD-L1 programmed cell death pathway is a popular cell death pathway in the research field. It is known to be an important pathway for apoptosis in many cell types, including T-cells, playing an effective role in immunomodulation, and immune tolerance as PD-1 has been shown to be expressed by different immune cells,

including B-cell, activated T-cells, macrophages, dendritic and natural killer cells (67,68,94). The pathway is also popular in the field of cancer research, and the reason it is heavily investigated is that the blockade of the PD-L1/PD-1 pathway exhibits an effect on activated T-cells, and clinical trials have already shown that anti-PD-1 drugs affected the regression of solid tumors. In addition to that, tumor cells may use the PD-1 pathway for evading the immune system, but by blocking the PD-1 pathway, the chance of cancer cells evading the immune system is eliminated. Clinical trials are underway investigating the targeted therapeutic blockade of PD-1 and PD-L1, such as the already approved FDA drugs nivolumab and ipilimumab, which are used for combination therapy of certain types of melanomas (69,95-97). As for MSCs, It has been reported in the literature that BMMSCs have the ability to express PD-L1 and directly induced T-cell suppression via the PDL1/PD1 pathway highlighting the importance of PD-L1 in BMMSC mediated immunomodulation and immune tolerance through T-cells (72). While BMMSCs are known to only express PD-L1 and not PD-1, dental tissue-derived stem cells like DPSCs and SHED are shown to express both PD-1 and PD-L1. For PD-L1, it has been shown to be expressed in the cytoplasm of the cells, while PD-1 is expressed in the membrane of the cells. PD-1 also has an important role in maintaining neural crest-derived dental pulp MSCs as it has been identified to participate in proliferation maintenance (98).

Furthermore, as the gingiva contains dental tissue-derived stem cells, and it also is known to contain roughly 90% neural crest-derived GMSCs and 10% from the mesoderm, and it had the ability to induce activated T-cell apoptosis in-vitro

(63). Therefore, we tested the PD-1/PD-L1 pathway, and we hypothesized that GMSCs being a dental tissue-derived stem cell population expresses PD-L1 like DPSCs and SHED and that PD-L1 pathway is the pathway in which GMSCs effect is seen in the ovariectomized mice model. To test this hypothesis, we utilized the siRNA approach to knockdown PD-L1 in GMSCs and used them for our transplantation. Our findings revealed that a single siPdl1 GMSCs transplantation was not successful in improving the bone phenotype in the OVX mice, this was also tested by scanning the femurs and analyzing the BMD, Total bone Volume, as well as testing measuring femurs levels of bone trabeculation, osteoclasts numbers, and fatty marrow levels which were confirmatory to the computed microtomography analysis of femurs. These data suggested that the effect on the bone and BMMSCs that we saw as a result of a GMSCs infusion in the OVX mouse model involves the PDL1/PD1 pathway.

Furthermore, to verify the involvement of PD-L1 in the GMSCs-mediated effect we utilized the use of an anti-PDL1 drug (Atezolizumab) and tested the effect on two groups, a wild type GMSCs-treated group receiving a placebo of PBS and wild type GMSCs treated group receiving two injections of Atezolizumab twice in a period of four weeks after the GMSCs treatment. The placebo group showed a significant increase in BV/TV, BMD values as measured and analyzed by computed microtomography in comparison to the Atezolizumab drug treatment group, this verifies the involvement of PD-L1 as in immune checkpoint for GMSCs mediated effect in the OVX mouse model, we utilized the drug Atezolizumab in our experiment as it has been approved recently by the FDA for treatment in multiple

cancer types pertaining to the lungs, and breasts in humans, it targets reestablishing anti-tumor T-cell activity by the blockade of PD-L1 protein which the expression of decreases T-cell anti-tumor activity (99-101). In our study, by witnessing a diminished effect of GMSCs infusion on the OVX bone phenotype, we confirm the role of PD-L1 as an immune checkpoint in the GMSCs-mediated effect in the ovariectomized mouse model. In addition to that, we tested the influence of GMSCs and siPdl1 GMSCs on the population of T-cells of mice and saw that the ovariectomized mice had a markedly higher level of Th-1 and Th-17, and a lower level of T-regs as determined by FACS. The levels of Th-1 and Th-17 in the GMSCs treated mice were significantly lowered when compared to the OVX group, and the T-regs were higher. The siPdl1 GMSCs treated mice had a similar expression of Th1, T-reg to that in OVX mice, and a less of similarity in Th-17. These data of T-cells subsets confirm the ability of GMSCs transplantation to reduce the levels of Th-1, Th-17 expression, and elevate T-reg expression leading to immune regulation. Lastly, when we tested the abilities of GMSCs and siPdl1 GMSCs to induce T-cell apoptosis in vitro, we observed a marked elevation in the levels and capabilities of WT GMSCs to induce T-cell apoptosis when compared to those of siPdl1-GMSCs. This further confirms the importance of siPdl1 in the identified influence of GMSCs on T-cells.

# Conclusions

- Ovariectomy induced osteoporosis is a valid small animal model leading to significant deterioration of bone phenotype.
- A Single transplantation of GMSCs into the OVX model markedly improved the bone phenotype.
- A Single transplantation of GMSCs into OVX mice significantly improved the function of endogenous BMSC population and rescued them.
- FAS/FASL pathway is not the pathway of which GMSCs exert its effect in the OVX mice.
- GMSCs immune-mediated effect in the OVX mice is through PD-L1 immune checkpoint and the influence of transplantation on T-cell populations leads to immune tolerance.

# References

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. 2001. pp. 785–95. Available from: <http://proxy.library.upenn.edu:2214/journals/jama/fullarticle/193534>
2. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int.* 1992 Nov;2(6):285–9.
3. Hildebolt CF. Osteoporosis and oral bone loss. *Dentomaxillofac Radiol.* 1997 Jan;26(1):3–15.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843. 1994 Jul 29;:1–136.
5. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. *Journal of bone and mineral research.* John Wiley & Sons, Ltd; 1997 Jan;12(1):24–35.
6. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet.* 2002 Jun 1;359(9321):1929–36.
7. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. *Epidemiol Rev.* 1985;7:178–208.
8. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. *Osteoporos Int.* 1994 Nov;4(6):368–81.
9. Wickham R. Osteoporosis Related to Disease or Therapy in Patients With Cancer. *Clinical Journal of Oncology Nursing.* 2011 Nov 26;15(6):E90–E104.
10. Research on the menopause in the 1990s. Report of a WHO Scientific Group. *World Health Organ Tech Rep Ser.* 1996;866:1–107.
11. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. *Arch Gen Psychiatry.* American Medical Association; 2006 Apr;63(4):385–90.

12. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. *Obstet Gynecol.* 2000 Sep;96(3):351–8.
13. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. *Osteoporos Int.* 1998;8 Suppl 4:S7–80.
14. Lerner UH. Bone remodeling in post-menopausal osteoporosis. *Journal of Dental Research.* 2006 Jul;85(7):584–95.
15. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *J Clin Invest.* 2005 Dec;115(12):3318–25.
16. Pfeilschifter J, Köditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. *Endocrine Reviews.* 2002 Feb;23(1):90–119.
17. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. *Journal of bone and mineral research.* John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR); 1996 Aug;11(8):1043–51.
18. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. *J Clin Invest.* American Society for Clinical Investigation; 2000 Nov;106(10):1229–37.
19. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. *J Clin Invest.* 2007 Jan;117(1):122–32.
20. Benedusi V, Martini E, Kallikourdis M, Villa A, Meda C, Maggi A. Ovariectomy shortens the life span of female mice. *Oncotarget. Impact Journals;* 2015 May 10;6(13):10801–11.
21. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. *Curr Mol Med.* 2002 Sep;2(6):571–7.
22. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. *Osteoporos Int.* Springer-Verlag; 2005 May;16(5):468–74.
23. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. *Calcified Tissue International.* 2004 Feb;74(2):129–35.



24. Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. *IJWH*. 2015;7:7–17.
25. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *Journal of Oral Maxillofacial Surgery*. 2003 Sep;61(9):1115–7.
26. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. *J Bone Miner Res*. 2009 Jun;24(6):1095–102.
27. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002 Jul 17;288(3):321–33.
28. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. *Endocrine Reviews*. 2002 Aug;23(4):524–8.
29. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. *J Natl Cancer Inst*. 1998 Jun 3;90(11):814–23.
30. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med*. 2006 Jul 13;355(2):125–37.
31. Osagie-Clouard L, Sanghani A, Coathup M, Briggs T, Bostrom M, Blunn G. Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation. *Bone Joint Res. Bone and Joint Research*; 2017 Jan;6(1):14–21.
32. Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. *J Clin Endocrinol Metab*. 2001 Mar;86(3):957–64.
33. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. *Toxicol Pathol [Internet]*. 2002 May;30(3):312–21. Available from: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=12051548&retmode=ref&cmd=prlinks>

34. american society of gene and cell therapy [Internet]. [cited 2017 Aug 7]. Available from: <http://www.asgct.org/general-public/educational-resources/gene-therapy--and-cell-therapy-defined>
35. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. *Bmc medicine*. BioMed Central; 2011 May 10;9(1):52–7.
36. Afanasyev BV, Elstner EE, Zander AR. A.J Friedenstein, founder of the mesenchymal stem cell concept. 2009 Apr 22;;1–4.
37. Pittenger MF. Multilineage Potential of Adult Human Mesenchymal Stem Cells. *Science*. American Association for the Advancement of Science; 1999 Apr 2;284(5411):143–7.
38. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. *Nat Rev Immunol* [Internet]. 2008 Sep;8(9):726–36. Available from: <http://www.nature.com/doi/10.1038/nri2395>
39. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. *Biosci Rep* [Internet]. 2015 Apr 28;35(2):1–18. Available from: <http://bioscirep.org/cgi/doi/10.1042/BSR20150025>
40. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–7.
41. Huang GTJ, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. *Journal of Dental Research*. 2009 Sep;88(9):792–806.
42. [clinicaltrials.gov](https://www.clinicaltrials.gov) [Internet]. NIH; [cited 2017 Aug 7]. Available from: <https://www.clinicaltrials.gov/ct2/results?cond=&term=MSC+cell+therapy&cntry1=&state1=&recrs=>
43. Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci USA*. 2000 Dec 5;97(25):13625–30.
44. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA*. 2003 May 13;100(10):5807–12.
45. Seo B-M, Miura M, Gronthos S, Bartold PM, Batouli S, Brahimi J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet*. 2004 Jul;364(9429):149–55.

46. Jo Y-Y, Lee H-J, Kook S-Y, Choung H-W, Park J-Y, Chung J-H, et al. Isolation and characterization of postnatal stem cells from human dental tissues. *Tissue Engineering*. 2007 Apr;13(4):767–73.
47. Morsczeck C, Götz W, Schierholz J, Zeilhofer F, Kühn U, Möhl C, et al. Isolation of precursor cells (PCs) from human dental follicle of wisdom teeth. *Matrix Biol*. 2005 Apr;24(2):155–65.
48. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. *J Immunol* [Internet]. 2009 Dec 15;183(12):7787–98. Available from: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19923445&retmode=ref&cmd=prlinks>
49. Marrelli M, Paduano F, Tatullo M. Cells isolated from human periapical cysts express mesenchymal stem cell-like properties. *Int J Biol Sci*. 2013;9(10):1070–8.
50. Chamieh F, Collignon A-M, Coyac BR, Lesieur J, Ribes S, Sadoine J, et al. Accelerated craniofacial bone regeneration through dense collagen gel scaffolds seeded with dental pulp stem cells. *Nature Publishing Group*. Nature Publishing Group; 2016 Nov 28;:1–11.
51. Kushnerev E, Shawcross SG, Sothirachagan S, Carley F, Brahma A, Yates JM, et al. Regeneration of Corneal Epithelium With Dental Pulp Stem Cells Using a Contact Lens Delivery System. *Invest Ophthalmol Vis Sci*. 2016 Oct 1;57(13):5192–8.
52. Yamaza T, Kentaro A, Chen C, Liu Y, Shi Y, Gronthos S, et al. Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. *Stem Cell Res Ther*. BioMed Central; 2010 Mar 15;1(1):5–10.
53. Fujii H, Matsubara K, Sakai K, Ito M, Ohno K, Ueda M, et al. Dopaminergic differentiation of stem cells from human deciduous teeth and their therapeutic benefits for Parkinsonian rats. *Brain Research*. Elsevier; 2015 Jul 10;1613(C):59–72.
54. Kanafi MM, Rajeshwari YB, Gupta S, Dadheech N, Nair PD, Gupta PK, et al. Transplantation of islet-like cell clusters derived from human dental pulp stem cells restores normoglycemia in diabetic mice. *Cytotherapy*. 2013 Oct;15(10):1228–36.
55. Yamaza T, Alatas FS, Yuniartha R, Yamaza H, Fujiyoshi JK, Yanagi Y, et al. In vivo hepatogenic capacity and therapeutic potential of stem cells

- from human exfoliated deciduous teeth in liver fibrosis in mice. *Stem Cell Res Ther. Stem Cell Research & Therapy*; 2015 Sep 5;:1–16.
56. Jee WS, Yao W. Overview: animal models of osteopenia and osteoporosis. *J Musculoskelet Neuronal Interact*. 2001 Mar;1(3):193–207.
  57. Antebi B, Pelled G, Gazit D. Stem cell therapy for osteoporosis. *Curr Osteoporos Rep. Springer US*; 2014 Mar;12(1):41–7.
  58. Hsiao FSH, Cheng CC, Peng SY, Huang HY, Lian WS, Jan ML, et al. Isolation of therapeutically functional mouse bone marrow mesenchymal stem cells within 3 h by an effective single-step plastic-adherent method. *Cell Proliferation*. 2010 Jun;43(3):235–48.
  59. Liu Y, Wang L, Liu S, Liu D, Chen C, Xu X, et al. Transplantation of SHED Prevents Bone Loss in the Early Phase of Ovariectomy-induced Osteoporosis. *Journal of Dental Research*. 2014 Sep 26;93(11):1124–32.
  60. Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* [Internet]. 2002 May 15;99(10):3838–43. Available from: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11986244&retmode=ref&cmd=prlinks>
  61. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* [Internet]. 2005 Feb 15;105(4):1815–22. Available from: <http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-04-1559>
  62. Harris DT. Stem Cell Banking for Regenerative and Personalized Medicine. *Biomedicines. Multidisciplinary Digital Publishing Institute*; 2014 Feb 26;2(1):50–79.
  63. Xu X, Chen C, Akiyama K, Chai Y, Le AD, Wang Z, et al. Gingivae contain neural-crest- and mesoderm-derived mesenchymal stem cells. *Journal of Dental Research* [Internet]. 2013 Sep;92(9):825–32. Available from: <http://jdr.sagepub.com/cgi/doi/10.1177/0022034513497961>
  64. Zhang Q-Z, Su W-R, Shi S-H, Wilder-Smith P, Xiang AP, Wong A, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. *Stem Cells* [Internet]. 2010 Oct;28(10):1856–68. Available from: <http://doi.wiley.com/10.1002/stem.503>
  65. Zhang Q, Nguyen AL, Shi S, Hill C, Wilder-Smith P, Krasieva TB, et al. Three-dimensional spheroid culture of human gingiva-derived

- mesenchymal stem cells enhances mitigation of chemotherapy-induced oral mucositis. *Stem Cells and Development*. 2012 Apr 10;21(6):937–47.
66. Wang F, Yu M, Yan X, Wen Y, Zeng Q, Yue W, et al. Gingiva-derived mesenchymal stem cell-mediated therapeutic approach for bone tissue regeneration. *Stem Cells and Development*. 2011 Dec;20(12):2093–102.
  67. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J. European Molecular Biology Organization*; 1992 Nov;11(11):3887–95.
  68. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. *Nat Rev Immunol. Nature Publishing Group*; 2017 Nov 13;18(3):153–67.
  69. Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. *Cancer Biology & Medicine*. 2018 May;15(2):116–23.
  70. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. *Trends in Immunology*. 2006 Apr;27(4):195–201.
  71. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev*. 2010 Jul;236(1):219–42.
  72. Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. *Stem Cells*. 2016 Oct 26;35(3):766–76.
  73. Cauley JA. Public health impact of osteoporosis. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 2013 Oct;68(10):1243–51.
  74. Cawthon PM. Gender differences in osteoporosis and fractures. *Clin Orthop Relat Res. Springer-Verlag*; 2011 Jul;469(7):1900–5.
  75. kennel KA, drake MT. Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. 2009 Jun 17;:1–7.
  76. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. *Rev Endocr Metab Disord. Kluwer Academic Publishers-Plenum Publishers*; 2006 Oct 17;7(1-2):113–21.
  77. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. *Eur J Immunol. John Wiley & Sons, Ltd*; 2006 Oct;36(10):2566–73.

78. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? *Trends in Immunology*. 2007 May;28(5):219–26.
79. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. *Transplantation*. 2009 May 15;87(9 Suppl):S45–9.
80. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. *Proc Natl Acad Sci USA*. National Academy of Sciences; 1991 Jun 15;88(12):5134–8.
81. Cioffi M, Esposito K, Vietri MT, Gazzerro P, D'Auria A, Ardovino I, et al. Cytokine pattern in postmenopause. *Maturitas*. 2002 Mar 25;41(3):187–92.
82. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. *Proc Natl Acad Sci USA* [Internet]. National Acad Sciences; 2001 Nov 20;98(24):13960–5. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.251534698>
83. Thorndike EA, Turner AS. In search of an animal model for postmenopausal diseases. *Front Biosci*. 1998 Apr 16;3(3):c17–26.
84. Campbell GM, Sophocleous A. Quantitative analysis of bone and soft tissue by micro-computed tomography: applications to ex vivo and in vivo studies. *BoneKEY Reports*. Nature Publishing Group; 2014;3:564–12.
85. Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. Zwaka T, editor. *PLoS ONE* [Internet]. 2008 Jul 9;3(7):e2615–9. Available from: <http://dx.plos.org/10.1371/journal.pone.0002615>
86. Xu L, Liu Y, Sun Y, Bin Wang, Xiong Y, Lin W, et al. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. *Stem Cell Research & Therapy*; 2017 Dec 1;:1–11.
87. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZM, Cristofaro MA, Tamone C, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. *Bone*. 2008 Jul;43(1):92–100.
88. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation

and lifespan through IFN-gamma-induced class II transactivator. *Proc Natl Acad Sci USA*. National Academy of Sciences; 2003 Sep 2;100(18):10405–10.

89. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. *Cell Stem Cell*. 2012 May 4;10(5):544–55.
90. Krammer PH. CD95's deadly mission in the immune system. *Nature*. 2000 Oct 12;407(6805):789–95.
91. Nagata S. Fas-induced apoptosis. *Intern Med*. The Japanese Society of Internal Medicine; 1998 Feb;37(2):179–81.
92. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell*. 1993 Dec 17;75(6):1169–78.
93. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. *Cell Death Differ*. 2003 Jan;10(1):26–35.
94. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. *Int Immunol*. 1996 May;8(5):765–72.
95. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. *Trends in Molecular Medicine*. Elsevier Ltd; 2015 Jan 1;21(1):24–33.
96. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. *Clin Immunol*. Elsevier Inc; 2014 Jul;153(1):145–52.
97. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015 Apr 3;348(6230):56–61.
98. Liu Y, Jing H, Kou X, Chen C, Liu D, Jin Y, et al. PD-1 is required to maintain stem cell properties in human dental pulp stem cells. *Cell Death Differ*. Springer US; 2018 Jul;25(7):1350–60.
99. Tie Y, Yang H, Zhao R, Zheng H, Yang D, Zhao J, et al. Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis. *DDDT*. 2019;13:523–38.
100. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/ PD-L1 blockade via anti-PD-L1 antibodies

atezolizumab and durvalumab. Nature Publishing Group. Springer US; 2017 Jul 7;;1–12.

101. saleh N, copur MS, editors. Atezolizumab and Its Many Uses | Cancer Network [Internet]. Vol. 33. 2019 [cited 2019 Nov 21]. pp. 1–5. Available from: <https://www.cancernetwork.com/immuno-oncology/atezolizumab-and-its-many-uses>